Patent Grant
11976292
The present invention relates generally to the field of viral vectors and systems for the delivery of genes and other therapeutic, diagnostic, or research uses. More specifically, embodiments of the present invention relate to non-integrating viral vectors and systems for the delivery of genes and other therapeutic, diagnostic, or research uses.
Viral vectors have been used to transduce genes and other therapeutic nucleic acid constructs into target cells owing to their specific virus envelope-host cell receptor interactions and viral mechanisms for gene expression. As a result, viral vectors have been used as vehicles for the transfer of genes into many different cell types including, but not limited to, isolated tissue samples, tissue targets in situ and cultured cell lines. The ability to both introduce and express foreign genes in a cell is useful for the study of gene expression and the elucidation of cell lineages and pathways as well as providing the potential for therapeutic interventions such as gene therapy and various types of immunotherapy.
Several viral systems including lentivirus murine retrovirus, adenovirus, and adeno-associated virus have been proposed as potential therapeutic gene transfer vectors. However, many hurdles have prevented robust utilization of these as approved therapeutics. Research and development hurdles include, but are not limited to, stability and control of expression, genome packaging capacity, and construct-dependent vector stability. In addition, in vivo application of viral vectors can be limited by host immune responses against viral structural proteins and/or transduced gene products, which can result in deleterious anti-vector immunological effects.
Researchers have attempted to find stable expression systems as a way of overcoming some of these hurdles. One approach utilizes recombinant polypeptides or gene regulatory molecules, including small RNA, in such expression systems. These systems employ chromosomal integration of a transduced retrovirus genome, or at least a portion thereof, into the genome of the host cell. An important limitation with these approaches is that the sites of gene integration are generally random, and the number and ratio of genes integrating at any particular site are often unpredictable. Thus, vectors that rely on chromosomal integration result in permanent maintenance of the recombinant gene that may exceed the therapeutic interval, and plasmid or other non-replicating DNA is poorly controlled and may decay before completing a desired therapeutic interval.
Another approach is the use of a transient expression system. Under a transient expression system, the expression of the gene of interest is based on non-integrated plasmids, and hence the expression is typically lost as the cell undergoes subsequent division or the plasmid vectors are destroyed by endogenous nucleases. Accordingly, transient gene expression systems typically do not lead to sufficient expression over time and typically require repeated treatments, which are generally understood to be undesirable features.
A stable viral delivery system and methods are provided. In various aspects, the delivery system includes a transient expression system. According to one aspect, the delivery system is non-integrating. In another aspect the delivery system is both non-integrating and transient.
In various aspects and embodiments, the system variously includes one or all of a viral carrier, wherein the viral carrier contains a defective integrase gene; a heterologous viral episomal origin of DNA replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of DNA replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. The viral carrier may be a lentivirus. The heterologous viral episomal origin of DNA replication may be from a papillomavirus. The heterologous viral episomal origin of DNA replication may be from a human papillomavirus or a bovine papillomavirus.
The heterologous viral episomal origin of DNA replication may be from a human papillomavirus type 16 (HPV16). The heterologous viral episomal origin of DNA replication may be from a long control region (LCR) of HPV16. The heterologous viral episomal origin of DNA replication may include SEQ ID NO: 1. Optionally, the heterologous viral episomal origin of DNA replication may include a 5′ truncation of SEQ ID NO: 1. The heterologous viral episomal origin of DNA replication may include a 5′ truncation of at least about 200 nucleotides, or at least about 300 nucleotides, or at least about 400 nucleotides, or at least about 500 nucleotides, or at least about 600 nucleotides, or at least about 700 nucleotides of SEQ ID NO: 1. The heterologous viral episomal origin of DNA replication may include at least about 80% sequence identity, or at least about 85% sequence identity, or at least about 90% sequence identity, or at least about 95% sequence identity, or at least about 98% sequence identity with Frag 1 (SEQ ID NO: 2) (also referred to herein as Fragment 1), or Frag 2 (SEQ ID NO: 3) (also referred to herein as Fragment 2), or Frag 3 (SEQ ID NO: 4) (also referred to herein as Fragment 3), or Frag 4 (SEQ ID NO: 5) (also referred to herein as Fragment 4) of the LCR of HPV16. The heterologous viral episomal origin of DNA replication may include Frag 1 (SEQ ID NO: 2), or Frag 2 (SEQ ID NO: 3), or Frag 3 (SEQ ID NO: 4), or Frag 4 (SEQ ID NO: 5) of the LCR of HPV16.
The at least one initiator protein specific for the heterologous viral episomal origin of DNA replication may include E1 or an operative fragment thereof. The at least one initiator protein specific for the heterologous viral episomal origin of DNA replication may include E2 or an operative fragment thereof. The at least one initiator protein specific for the heterologous viral episomal origin of DNA replication may include EBNA-1 or an operative fragment thereof. Optionally, the system may include at least two initiator proteins specific for the heterologous viral episomal origin of replication. The at least two initiator proteins specific for the heterologous viral episomal origin of DNA replication may include either of E1 or E2, alone or in combination, or operative fragments thereof. The sequence encoding the at least one initiator protein may be present on a single discrete plasmid or a non-integrating viral vector. Optionally, the system may include at least two initiator proteins specific for the heterologous viral episomal origin of DNA replication, wherein the sequence encoding the at least two initiator proteins may be present on a single discrete plasmid or a non-integrating viral vector. Optionally, the system may include at least two initiator proteins specific for the heterologous viral episomal origin of DNA replication, wherein the sequence for a first initiator protein and the sequence for a second initiator protein may be present on discrete plasmids or non-integrating viral vectors.
In respect of the disclosed non-integrating viral delivery system, the at least one gene product may include an antibody, an antibody fragment, or a growth factor. The antibody may include an anti-HER2 antibody or a fragment thereof. The growth factor may include vascular endothelial growth factor (VEGF) or a variant thereof. The miRNA may include a CCR5 miRNA.
In another aspect, a pharmaceutical composition is disclosed. The pharmaceutical compositions include the non-integrating viral delivery system disclosed herein and at least one pharmaceutically acceptable carrier.
In another aspect, a method of expressing at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest in a cell is provided. The method includes contacting a cell with an effective amount of a non-integrating viral delivery system, wherein the system includes a viral carrier, wherein the viral carrier contains one or all of a defective integrase gene; a heterologous viral episomal origin of DNA replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of DNA replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest.
In another aspect, a method of expressing at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest in a subject in need thereof is provided. The method includes administering to the subject in need thereof an effective amount of a non-integrating viral delivery system, wherein the system includes a viral carrier, wherein the viral carrier contains one or all of a defective integrase gene; a heterologous viral episomal origin of DNA replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of DNA replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. The sequence encoding the at least one initiator protein may be present on a single discrete plasmid, and the at least one initiator protein may include either of E1 or E2, alone or in combination, or operative fragments thereof. The method may further involve administering to the subject in need thereof a first amount of the single discrete plasmid to initiate a first level of expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. The method may further involve administering to the subject in need thereof a second amount of the single discrete plasmid to initiate a second level of expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. In situations when the second amount is lower than the first amount, the level of expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest may be reduced. In situations when the second amount is higher than the first amount, the level of expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest may be increased.
In another aspect, the non-integrating viral delivery system disclosed herein is optimized to produce a low level of basal expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. The heterologous viral episomal origin of DNA replication may include at least about 80% sequence identity, or at least about 85% sequence identity, or at least about 90% sequence identity, or at least about 95% sequence identity, or at least about 98% sequence identity with SEQ ID NO: 1 or Frag 1 (SEQ ID NO: 2) of the LCR of HPV16.
In another aspect, the non-integrating viral delivery system disclosed herein is optimized to produce a low level of basal expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest, and the heterologous viral episomal origin of DNA replication may include SEQ ID NO: 1 or Frag 1 (SEQ ID NO: 2) of the LCR of HPV16.
In another aspect, the non-integrating viral delivery system disclosed herein is optimized to produce a moderate level of basal expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest, and the heterologous viral episomal origin of DNA replication may include at least about 80% sequence identity, or at least about 85% sequence identity, or at least about 90% sequence identity, or at least about 95% sequence identity, or at least about 98% sequence identity with Frag 2 (SEQ ID NO: 3), Frag 3 (SEQ ID NO: 4), or Frag 4 (SEQ ID NO: 5) of the LCR of HPV16. The system may be optimized to produce a moderate level of basal expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest, and the heterologous viral episomal origin of DNA replication may include Frag 2 (SEQ ID NO: 3), Frag 3 (SEQ ID NO: 4), or Frag 4 (SEQ ID NO: 5) of the LCR of HPV16.
In another aspect, a method of selecting an optimized non-integrating viral delivery system is disclosed. The method involves selecting a level of basal expression. Thereafter, when a level X is selected, a corresponding Y is selected, wherein Y corresponds to a heterologous viral episomal origin of DNA replication selected to be incorporated into the non-integrating viral delivery system, whereby when X=low; Y comprises SEQ ID NO: 1 or Frag 1 (SEQ ID NO: 2); and when X=moderate; Y comprises Frag 2 (SEQ ID NO: 3), Frag 3 (SEQ ID NO: 4), or Frag 4 (SEQ ID NO: 5) of the LCR of HPV16.
Further aspects include methods of treating, for example, an infectious disease. Further aspects include methods of preventing an infectious disease. In another aspect, methods of enhancing wound healing are disclosed. In another aspect, methods of treating a bone injury are disclosed. Further aspects include methods of treating a hereditary disease using the systems detailed herein.
The foregoing general description and following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following brief description of the drawings and detailed description of the invention.
Disclosed herein is a stable viral delivery system and methods. In various aspects, the delivery system includes a transient expression system. According to one aspect, the delivery system is non-integrating. In another aspect the delivery system is both non-integrating and transient.
In further aspects, non-integrating, episomally replicating viral vectors (e.g., lentiviral vectors) and methods of using the same are provided. Episomally replicating vectors of the present invention can contain viral components from viruses like Papovaviridae (e.g., bovine papillomavirus or BPV) or Herpesviridae (e.g., Epstein Barr Virus or EBV) or Hepadnaviridae (e.g., Hepatitis B Virus or HBV). Episomal replicating vectors derived from these viruses may contain a replication origin and at least one viral trans-acting factor, e.g., an initiator protein, such as E1 for BPV and EBNA-1 for EBV or HBV polymerase or terminus binding protein of Adenovirus. The process of episomal replication typically incorporates both host cell replication machinery and viral trans-acting factors.
By using heterogeneous viral origins of replication, novel vectors can be engineered with an “off” switch for expression of viral proteins required to recognize the origin of replication. Switching off DNA replication will cause therapeutic DNA levels to dramatically drop over time. Without wishing to be bound by any particular theory, it is believed that the non-replicating DNA simply degrades, such as by nuclease activity and as the host cell undergoes natural apoptosis (cell death) events over time. Eventually such non-replicating DNA may be non-detectible and completely or nearly cleared from the patient over time.
The disclosed systems and methods include reducing or preventing toxicity and toxic effects from over-expression or prolonged expression of transduced genes. Eliminating the gene once DNA replication ceases prevents unwanted gene expression or knockdown of host gene expression in the future. Likewise, combining the benefits of episomal replication into a heterogeneous viral system provides for a platform that can safely and efficiently transduce genes of interest into a variety of cell types.
Papillomavirus
Papillomaviruses replicate primarily as episomes in mammalian cells. Action of the viral E1 protein, which functions as a DNA helicase, on the viral origin of DNA replication (ori) drives the production of hundreds to thousands of DNA copies per cells depending on differentiation status of infected epithelial cells. Attempts have been made to develop papillomavirus-based gene delivery systems using what became known as “shuttle plasmids.” With a bacterial origin of DNA replication to allow production of DNA in E. coli and a papillomavirus ori to allow episomal replication in mammalian cells, a number of studies have been performed to demonstrate safety and durability of gene expression. In most cases, the ori came from bovine papillomavirus.
Papillomaviruses have evolved to infect epidermal and epithelial cells. As infected cells differentiate from basal to luminal surfaces, papillomaviruses increase DNA replication and copy number becomes very high until a tremendous dose of virus is released at the lumenal surface. This makes papillomaviruses highly contagious as is apparent from human papillomavirus. The surge in copy number is due primarily to host factors. However, this feature of papillomavirus can be exploited to target transient gene therapy to epidermal and epithelial surfaces.
Certain features of papillomavirus are used in accordance with various aspects and embodiments of the present invention for driving expression and replication of an episomal vector, as well as targeting expression of the vector to specific cell types.
Epstein Barr Virus (EBV)
Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses, and most people become infected with EBV at some point in their lives.
EBV is a double-stranded DNA virus that contains approximately 85 genes; EBV is known to infect B cells and epithelial cells. EBV is capable of both lytic and latent replication, the latter of which results in a circularized version of the EBV genome translocating to the host cell nucleus where it may be replicated by host cell DNA polymerases.
EBV can undergo latent replication via at least three distinct pathways, but each one involves the expression of Epstein-Barr virus nuclear antigen 1 (EBNA-1), a protein that binds the episomal replication origin and mediates partitioning of the episome during division of the host cell. EBNA-1 plays an integral role in EBV gene regulation, replication, and episomal maintenance.
Certain features of EBV are used in accordance with various aspects and embodiments of the present invention.
Hepatitis B Virus (HBV)
Hepatitis B virus (HBV) is a member of the hepadnavirus family. It is a common human virus associated with progressive liver fibrosis, hepatitis and hepatocellular carcinoma.
HBV is a double stranded DNA virus that replicates through an RNA intermediate and depends on a viral polymerase. Stable maintenance of HBV in liver cells is due to the presence of covalently-closed viral DNA circular forms that are difficult to eradicate.
Thus, certain features of HBV are used in accordance with various aspects and embodiments of the present invention.
Retrovirus
Retrovirus is a virus family characterized by encoding a reverse transcriptase capable of generating DNA copies from RNA templates and integration of proviruses into the host cell chromosome. Lentivirus is a genus of retroviruses that can deliver a significant amount of viral nucleic acid into a host cell. Lentiviruses are characterized as having a unique ability to infect/transduce non-dividing cells, and following transduction, lentiviruses integrate their nucleic acid into the host cell's chromosomes.
Infectious lentiviruses have three main genes coding for the virulence proteins gag, pol, and env, and two regulatory genes including tat and rev. Depending on the specific serotype and virus, there may be additional accessory genes that code for proteins involved in regulation, synthesis, and/or processing viral nucleic acids and other replicative functions including counteracting innate cellular defenses against lentivirus infection.
Lentiviruses contain long terminal repeat (LTR) regions, which may be approximately 600 nt long. LTRs may be segmented into U3, R, and U5 regions. LTRs can mediate integration of retroviral DNA into the host chromosome via the action of integrase.
Alternatively, without functioning integrase, the LTRs may be used to circularize the viral nucleic acid.
Viral proteins involved in early stages of lentivirus replication include reverse transcriptase and integrase. Reverse transcriptase is a virally encoded, RNA-dependent DNA polymerase. The enzyme uses a viral RNA genome as a template for the synthesis of a complementary DNA copy. Reverse transcriptase also has RNaseH activity for the destruction of the RNA-template that is necessary to DNA second strand synthesis to complete production of the double-stranded DNA ready for integration. Integrase binds both the viral cDNA generated by reverse transcriptase and the host DNA. Integrase processes the LTR before inserting the viral genome into the host DNA. Tat acts as a trans-activator during transcription to enhance the initiation and elongation of RNA copies made from viral DNA. The rev responsive element acts post-transcriptionally, regulating mRNA splicing and transport to the cytoplasm.
Certain features of retroviruses, including lentiviruses, are used in accordance with various aspects and embodiments of the present invention.
Vector-in-Vector System
A novel vector-in-vector (VIV) system is provided that can precisely regulate the delivery and expression of genes by combining desirable features from various viral species. Many viral vectors, including lentivirus (LV) platforms, may be used. Lentiviral transduction, like most other forms of stable transduction, results in chromosomal integration of the LV payload (e.g., gene of interest). In accordance with various aspects, chromosomal integration is abolished through selective mutations that inactivate the viral integrase gene.
The papillomavirus ori plus E1 protein, or the EBV ori plus EBNA-1 or the Hepadnavirus termini plus viral polymerase are used herein, as part of the genetic cargo of a heterologous virus that would not ordinarily be able to be maintained episomally. Incorporating this heterogeneous viral replication machinery into a lentiviral vector leaves approximately 5 kb of additional cargo space available to accommodate therapeutic genes of interest.
Additionally, other control elements can be incorporated into the disclosed VIV system. As a non-limiting example, the expression of E1 or E2 or EBNA-1 or HBV polymerase can be driven by an inducible promoter. Further, as a non-limiting example, E1 and/or E2 can be expressed using plasmids or non-integrating viral vectors. Numerous types of inducible promoters are known in the art, and for the purposes of this invention, inducible promoters can include but are not limited to promoters that respond to antibiotics (i.e., tetracyclines, aminoglycosides, penicillins, cephalosporins, polymyxins, etc.) or other drugs, copper and other metals, alcohol, steroids, light, oxygen, heat, cold, or other physical or chemical stimulation. For example, a method of using the disclosed viral system includes employing a tetracycline-inducible gene expression that depends upon a constant supply of the drug for expression of the cargo genes. A compound used to induce the inducible promoter may be added once or repeatedly depending on the duration of episomal replication and timing of cargo delivery that is desired. DNA replication and maintenance of the episome depends variously on E1, E2 and/or EBNA-1 induction, which in turn depends upon an inducer of gene expression (i.e., tetracycline).
An exemplary VIV system is shown in
A further exemplary diagram of a VIV system is shown in
A further exemplary diagram of a VIV system is shown in
Suitable expression of the cargo may be determined by an appropriate assay. For example, DNA copy numbers can be measured by quantitative PCR. Protein products translated from non-limiting examples such as Vector 1 or Vector 19 (as described herein) can be measured, for example, by analytical flow cytometry. An ELISA assay may be used to detect the presence of certain cargo, such as a secreted protein, such as VEGF. A Western blot technique may also be used to detect certain cargo such as an antibody, such as anti-EGFR. Further, monitoring a reduction in cell surface expression of a cargo protein, such as a chemokine receptor such as CCR5, can also be employed.
In respect of the cargo, and serving as a non-limiting example, the gene encoding platelet-derived growth factor (PDGF) can be incorporated as a gene along with shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest into a VIV used to promote wound healing. The disclosed VIV system is not limited to a particular type of gene or sequence that can be expressed.
The disclosed VIV can incorporate numerous therapeutic or prophylactic genes or sequences including, for example, sequences that encode antibodies directed to an antigen associated with an infectious disease or cancer (including antigens on replicating pathogens and antigens that are exogenous toxins and antigens on tumor cells), platelet derived growth factor, vascular endothelial growth factor, brain derived growth factor, nerve growth factor, human growth factor, human chorionic gonadotropin, cystic fibrosis transmembrane conductance regulator (CFTR), dystrophin or dystrophin-associated complex, phenylalanine hydroxylase, lipoprotein lipases, α- and/or β-thalassemias, factor VIII, bone morphogenetic proteins 1-4, cyclooxygenase 2, vascular endothelial growth factor, chemokine receptor CCR5, chemokine receptor CXCR4, chemokine receptor CXCR5, antisense DNA or RNA against autoimmune antigens involved in colitis, inflammatory bowel disease or Crohn's disease, small interfering RNA that are involved in addiction including miRNA regulating neural attenuation to opiates or alcohol, tumor suppressor genes, genes regulating cell survival including pro- or anti-apoptosis genes and pro- or anti-autophagy genes, genes encoding radiation resistance factors, genes encoding light emitting proteins used for tracking tumor cell metastasis or other cell trafficking phenomena, or a variety of other therapeutically useful sequences that may be used to condition the body for maximum effect of radiation, surgical or chemotherapeutics or to protect tissues against radiation, surgical or chemotherapeutics, to modify the host or graft tissues to improve organ transplantation or to suppress hyprerreactivity especially in the airway.
Without limiting any of the foregoing, cargo can include diagnostic proteins such as GRP and mCherry, as well as cDNAs, micoRNAs, shRNAs, and antibodies. Further, cargo can include specific cargo such as VEGF and BMP, as described herein.
In further aspects, it is desirable to maintain the genes in episomal form in a VIV system as a “safety switch.” For example, where a particular gene product is toxic, withdrawal of the inducer molecule will reduce or terminate DNA replication. Episome numbers will subsequently decline, and the gene and vector will eventually disappear. Unlike traditional regulated gene expression as the safety switch, the disclosed expression construct is degraded by endogenous nucleases and diluted by cell division until it has effectively disappeared, thereby preventing any short- or long-term breakthrough expression.
In accordance with a further aspect, maintaining a gene, gene product, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest in episomal form also allows for regulating the copy number over a broad range and at much higher levels than is achieved by traditional lentivirus transduction.
The disclosed VIV system presents numerous benefits. For instance, episomal DNA is less susceptible to chromosomal modification, which can lead to gene silencing of traditional transduction vectors. Likewise, VIV episomal DNA vectors support active gene delivery at least over short- to medium-range time intervals of about 1 to about 4 months, and possibly longer. In other embodiments of the invention, episomal DNA vectors support active gene delivery over a period of about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12 weeks or longer. In other embodiments, episomal DNA vectors support active gene delivery over a period of about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer. Any combination of these time periods can also be used in the methods of the invention, e.g., 1 month and 1 week, or 3 months and 2 weeks.
While there are benefits specifically associated with the use of a lentiviral carrier for incorporation of the disclosed VIV system, the disclosed system is not limited to a single type of viral vector. Any DNA virus or virus that uses a DNA intermediate can be used as a carrier for incorporating the VIV system herein, including but not limited to lentivirus, adeno-associated virus (AAV), adenovirus, vaccinia, herpes virus, measles virus, hepadnavirus, parvovirus and murine viruses.
Without limiting any of the foregoing, in an aspect of the invention, a non-integrating viral delivery system is disclosed. The system includes a viral carrier, wherein the viral carrier contains a one or more of a defective integrase gene; a heterologous viral episomal origin of replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. The viral carrier may be a lentivirus. The heterologous viral episomal origin of DNA replication may be from a papillomavirus. The heterologous viral episomal origin of DNA replication may be from a human papillomavirus or a bovine papillomavirus.
The heterologous viral episomal origin of DNA replication may be from a human papillomavirus type 16 (HPV16). The heterologous viral episomal origin of DNA replication may be from a long control region (LCR) of HPV16. The heterologous viral episomal origin of DNA replication may include SEQ ID NO: 1. Optionally, the heterologous viral episomal origin of DNA replication may include a 5′ truncation of SEQ ID NO: 1. The heterologous viral episomal origin of DNA replication may include a 5′ truncation of at least about 200 nucleotides, or at least about 300 nucleotides, or at least about 400 nucleotides, or at least about 500 nucleotides, or at least about 600 nucleotides, or at least about 700 nucleotides of SEQ ID NO: 1. The heterologous viral episomal origin of DNA replication may include at least about 80% sequence identity, or at least about 85% sequence identity, or at least about 90% sequence identity, or at least about 95% sequence identity, or at least about 98% sequence identity with Frag 1 (SEQ ID NO: 2), or Frag 2 (SEQ ID NO: 3), or Frag 3 (SEQ ID NO: 4), or Frag 4 (SEQ ID NO: 5) of the LCR of HPV16. The heterologous viral episomal origin of DNA replication may include Frag 1 (SEQ ID NO: 2), or Frag 2 (SEQ ID NO: 3), or Frag 3 (SEQ ID NO: 4), or Frag 4 (SEQ ID NO: 5) of the LCR of HPV16. Without limiting any of the foregoing or the Examples detailed herein, the genomic organization of the LCR is depicted in
The LCR fragments detailed herein can be selected and used depending on a disease target. As shown in
Accordingly, based on the intended disease target, a vector system can be designed using Quadrant 1, Quadrant 2, Quadrant 3, or Quadrant 4 components (see:
Accordingly, the selection process can be correlated to the LCR fragments employed herein thus rendering the disclosed systems highly adaptable depending on the disease target and the intended biological response.
The at least one initiator protein specific for the heterologous viral episomal origin of DNA replication may include E1 or an operative fragment thereof. The at least one initiator protein specific for the heterologous viral episomal origin of DNA replication may include E2 or an operative fragment thereof. The at least one initiator protein specific for the heterologous viral episomal origin of DNA replication may include EBNA-1 or an operative fragment thereof. Optionally, the system may include at least two initiator proteins specific for the heterologous viral episomal origin of replication. The at least two initiator proteins specific for the heterologous viral episomal origin of DNA replication may be E1 and E2 or operative fragments thereof. The sequence encoding the at least one initiator protein may be present on a single discrete plasmid. Optionally, the system may include at least two initiator proteins specific for the heterologous viral episomal origin of replication, wherein the sequence encoding the at least two initiator proteins may be present on a single discrete plasmid. Optionally, the system may include at least two initiator proteins specific for the heterologous viral episomal origin of replication, wherein the sequence for a first initiator protein and the sequence for a second initiator protein may be present on discrete plasmids.
In respect of the disclosed non-integrating viral delivery system, the at least one gene product may include an antibody, an antibody fragment, or a growth factor. The antibody may include an anti-HER2 antibody or a fragment thereof. The growth factor may include vascular endothelial growth factor (VEGF) or a variant thereof. The miRNA may include a CCR5 miRNA.
Methods
Aspects of the invention include methods of administering a VIV system to a patient in need thereof, wherein the VIV system encodes at least one, at least two, at least three, at least four, or at least five genes of interest. Given the versatility and therapeutic potential and the disclosed VIV system, a VIV system according to aspects of the invention may encode genes or nucleic acid sequences that include but are not limited to an antibody directed to an antigen associated with an infectious disease or a toxin produced by the infectious pathogen, platelet derived growth factor, vascular endothelial growth factor, brain derived growth factor, nerve growth factor, human growth factor, human chorionic gonadotropin, cystic fibrosis transmembrane conductance regulator (CFTR), dystrophin or dystrophin-associated complex, lipoprotein lipases, α- and/or β-thalassemias, factor VIII, bone morphogenetic proteins 1-4, cyclooxygenase 2, vascular endothelial growth factor, chemokine receptor CCR5, chemokine receptor CXCR4, chemokine receptor CXCR5, antisense DNA or RNA against autoimmune antigens involved in colitis, inflammatory bowel disease or Crohn's disease, small interfering RNA that are involved in addiction including miRNAs regulating neural attenuation to opiates or alcohol, tumor suppressor genes, genes regulating cell survival including pro- or anti-apoptosis genes and pro- or anti-autophagy genes, genes encoding radiation resistance factors, genes encoding light emitting proteins used for tracking tumor cell metastasis or other cell trafficking phenomena, or a variety of other therapeutically useful sequences that may be used to condition the body for maximum effect of radiation, surgical or chemotherapeutics or to protect tissues against radiation, surgical or chemotherapeutics, to modify the host or graft tissues to improve organ transplantation or to suppress hyprerreactivity especially in the airway.
Further, and without limiting any of the foregoing, in another aspect, a method of expressing at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest in a cell is provided. The method includes contacting the cell with an effective amount of a non-integrating viral delivery system, wherein the system includes a viral carrier, wherein the viral carrier contains a defective integrase gene; a heterologous viral episomal origin of replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest.
In another aspect, a method of expressing at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest in a subject in need thereof is provided. The method includes administering to the subject in need thereof an effective amount of a non-integrating viral delivery system, wherein the system includes a viral carrier, wherein the viral carrier contains a defective integrase gene; a heterologous viral episomal origin of replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. The sequence encoding the at least one initiator protein may be present on a single discrete plasmid, and the at least one initiator protein may be either of E1 or E2, alone or in combination, or fragments thereof. The method optionally includes administering to the subject in need thereof a first amount of the single discrete plasmid to initiate a first level of expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. The method optionally includes administering to the subject in need thereof a second amount of the single discrete plasmid to initiate a second level of expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. In situations when the second amount is lower than the first amount, the level of expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest may be reduced. In situations when the second amount is higher than the first amount, the level of expression of the at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest may be increased.
Infectious Disease
Methods of treating or preventing infectious disease are provided. Prophylactic delivery of monoclonal antibodies to high risk individuals is presently practiced, such as individuals at high risk of contracting an infectious disease, due to health status or geographic location. The prophylactic delivery includes delivery protective antibodies against a lethal viral agent, such as to protect individuals moving through an endemic region (e.g., military and aid workers entering an Ebola-infected region). Vaccines are largely untested for diseases such as Ebola or Lassa Fever virus or Dengue fever or Chikungunya virus or Plasmodium spp. causing malaria, and chronic expression of prophylactic antibody genes through the use of integrating vectors carries unknown health risks. Thus, there is a significant medical need for effective antibody expression that must be high but transient.
The disclosed VIV system and methods of delivering high copy numbers of a gene, gene product, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest for a limited period satisfy this medical need. A non-limiting example of a gene product that can be delivered for treating an infectious disease is an antibody specific for the infectious disease in question.
In one aspect, the invention is directed to methods of treating, preventing, or minimizing conditions, symptoms, or side effects associated with infectious disease. In certain embodiments, the infectious disease can be human immunodeficiency virus (HIV), human T cell leukemia virus, Ebola virus, Lassa fever virus, dengue fever, Zika virus, malaria, tuberculosis, rabies, vaccinia virus or other infectious diseases. In some embodiments, a VIV system can be administered prophylactically or following infection with an infectious disease.
In another aspect, a VIV system can be used to prevent an infectious disease. Subjects suspected of having an increased risk of contracting a particular infection disease can receive administrations of a prophylactically effective amount of a VIV encoding an antibody that specifically targets the infectious disease in question.
In certain embodiments, the infectious disease can be human immunodeficiency virus (HIV), human T cell leukemia virus, Ebola virus, Lassa fever virus, dengue fever, Zika virus, malaria, tuberculosis, rabies, vaccinia virus or other infectious diseases. In certain embodiments, a VIV vector can be administered prophylactically or following infection with an infectious disease.
Wound Healing
In another embodiment, the invention is directed to methods of treating, preventing, or minimizing conditions, symptoms, or side effects associated with wound healing. The disclosed composition can be administered systemically or directly to a wound after an accident, injury, or surgery. In the case of surgery, a VIV system may be administered prophylactically in order to expedite healing. In the case of a wound from an accident, injury, or surgery, a VIV system may be administered sometime after the formation of the wound. For instance, the VIV system may be administered within about 1, about 2, about 3, about 4, about 5, about 10, about 12, about 24, about 36, about 48, about 60, about 72, about 84, about 96, about 108, about 120, or about 168 hours of the formation of a wound.
Another application of the methods and compositions of the invention is transient delivery of VIV constructs capable of expressing platelet growth factor that would accelerate wound healing. A high dose of platelet-derived growth factor (PDGF), related growth factors, fragments thereof, and nucleotide mutants related thereto is required very quickly but transiently. The disclosed system and methods are ideal for this type of application.
Additional short-term applications include expression of brain-derived growth factor for intermittent treatment of alcohol abuse, nerve growth factor for spinal cord regeneration, and topical applications for skin conditions.
Bone Disease or Injury
In one embodiment, the disclosed invention is directed to a method of enhancing bone healing, comprising identifying a subject with a bone injury and administering to the subject a therapeutically effective amount of a viral delivery system according to the invention. The viral delivery system comprises a viral carrier, a heterologous viral episomal origin of replication, a sequence encoding an initiator protein specific for the heterologous viral episomal origin of replication, and at least one gene, gene product, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest, wherein the viral carrier has a defective integrase gene, and wherein expression of the sequence encoding the initiator protein specific for the heterologous viral episomal origin of DNA replication is under the control of an inducible promoter. The bone injury can be, for example, resulting from an accident, injury, or surgery and may be bone nonunion, or acute fracture or required spinal fusion. In some embodiments, the gene, gene product, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest encodes bone morphogenetic proteins 1-4 or cyclooxygenase-2 or vascular endothelial growth factor, or fragments thereof. Further, in certain embodiments mutants of the foregoing are preferable and are within the scope of the invention for treating a bone injury or related disease.
In one embodiment, the disclosed invention is directed to a method of enhancing bone healing, comprising identifying a subject with a bone disease and administering to the subject a therapeutically effective amount of a viral delivery system according to the invention. The viral delivery system comprises a viral carrier, a heterologous viral episomal origin of replication, a sequence encoding an initiator protein specific for the heterologous viral episomal origin of replication, and at least one gene, gene product, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest, wherein the viral carrier has a defective integrase gene, and wherein expression of the sequence encoding the initiator protein specific for the heterologous viral episomal origin of DNA replication is under the control of an inducible promoter. The bone disease can be, for example, resulting from an accident, injury, or surgery and may be bone nonunion, or acute fracture or required spinal fusion. Additionally, the bone disease may be from low bone density, low blood flow to the bone, aging, hereditary conditions, and the like. In some embodiments, the gene, gene product, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest encodes bone morphogenetic proteins 1-4 or cyclooxygenase-2 or vascular endothelial growth factor.
Hereditary Genetic Disease
In another embodiment, the invention is directed to methods of treating, preventing, or minimizing conditions, symptoms, or side effects associated with a hereditary genetic disease. Several examples of such hereditary genetic diseases are disclosed in Table 2 herein, along with the causal type of mutation and chromosome involved using the nomenclature below:
Current gene therapy includes efforts to edit genomic DNA through gene deletion, replacement, or re-sequencing. Various gene therapy systems known in the art, including Talen, CRISPR-Cas9, zinc finger endonuclease, TALEN, and others, rely on delivery of genetic material by lentivirus transduction. But, unlike the disclosed invention, these systems may have unexpected consequences if left active in cells for extended periods because active chromosome modification systems may alter unexpected sites, leading to new genetic diseases including cancer. Truly practical systems for modification of host DNA require transient, well-regulated expression through methods such as the method disclosed herein.
Thus, in one embodiment, the disclosed invention is directed to a method of treating a hereditary genetic disease, comprising identifying a subject with a hereditary genetic disease and administering to the subject a therapeutically effective amount of a viral delivery system according to the invention. The viral delivery system comprises a one or more of a viral carrier, a heterologous viral episomal origin of replication, a sequence encoding an initiator protein specific for the heterologous viral episomal origin of replication, and at least one gene, gene product, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest, wherein the viral carrier has a defective integrase gene, and wherein expression of the sequence encoding the initiator protein specific for the heterologous viral episomal origin of DNA replication is under the control of an inducible promoter. The hereditary genetic disease can be, for example, the diseases listed in Table 2, and in some embodiments, the gene, gene product, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest encodes non-mutated versions of the genes listed in Table 2. Without limiting the foregoing, the specific hereditary genetic disease can be CF and treatment can be pursued by expressing a non-mutated form of CFTR as detailed herein.
In another embodiment, a guide RNA target sequence is incorporated into the disclosed VIV system. Guide RNA are sequences used to target gene editing machinery to specific sites within the host genome that are mutated or otherwise require correction. Inclusion of guide RNA within the cargo of a VIV system allows for a modification of a section of a chromosome that requires correction, and the same modification will occur within VIV to accelerate degradation and/or dilution by the host. In certain embodiments of the invention, the disclosed viral delivery system comprises one or more of a viral carrier, a heterologous viral episomal origin of replication, a sequence encoding an initiator protein specific for the heterologous viral episomal origin of replication, at least one gene, shRNA, siRNA, miRNA, and/or other gene-silencing RNA of interest, and at least one guide RNA, wherein the viral carrier has a defective integrase gene, and wherein expression of the sequence encoding the initiator protein specific for the heterologous viral episomal origin of DNA replication is under the control of an inducible promoter.
Ex Vivo Modification of Cells or Tissues
In another aspect, the VIV system may be used to modify cells or tissues that are used for disease therapy. Cells may include, without limitation, primary cells such as lymphocytes, stem cells, epithelial cells, neural cells and others. For example, the VIV system may be used to modify lymphocytes that are redirected to specific disease including cancer, infectious disease or autoimmunity, and where long-term presence of genetically modified cells poses a health risk. For example, a VIV system may also be used to program pluripotent stem cells that require high levels of transcript factors for a defined interval and where the long-term presence of an integrated viral vector is undesirable. Suitable epithelial cells include those used for synthetic skin or other applications. These may require the expression of trophic or growth factors during the initial treatment that would be deleterious to function of the normal tissue after treatment and are best delivered by the VIV systems disclosed herein.
Doses and Dosage Forms
The disclosed VIV systems allow for short, medium, or long-term expression of genes or sequences of interest and episomal maintenance of the disclosed vectors. Accordingly, dosing regimens may vary based upon the condition being treated and the method of administration.
In one embodiment, VIVs may be administered to a subject in need in varying doses. Specifically, a subject may be administered ≥106 infectious doses (where 1 dose is needed on average to transduce 1 target cell). More specifically, a subject may be administered ≥107, ≥108, ≥109, or ≥1010 infectious doses. Upper limits of VIV dosing will be determined for each disease indication and will depend on toxicity/safety profiles for each individual product or product lot.
Additionally, VIVs may be administered once or twice a day. Alternatively, VIVs may be administered to a subject in need once a week, once every other week, once every three weeks, once a month, every other month, every three months, every six months, every nine months, once a year, every eighteen months, every two years, every 36 months, or every three years or more.
In various aspects and embodiments, VIVs are administered as a pharmaceutical composition. In embodiments, the pharmaceutical composition comprising VIV can be formulated in a wide variety of nasal, pulmonary, oral, topical, or parenteral dosage forms for clinical application. Each of the dosage forms can contain various disintegrating agents, surfactants, fillers, thickeners, binders, diluents such as wetting agents or other pharmaceutically acceptable excipients. The pharmaceutical composition comprising a VIV can also be formulated for injection.
The VIV composition can be administered using any pharmaceutically acceptable method, such as intranasal, buccal, sublingual, oral, rectal, ocular, parenteral (intravenously, intradermally, intramuscularly, subcutaneously, intracistemally, intraperitoneally), pulmonary, intravaginal, locally administered, topically administered, topically administered after scarification, mucosally administered, via an aerosol, or via a buccal or nasal spray formulation.
Further, the VIV composition can be formulated into any pharmaceutically acceptable dosage form, such as a solid dosage form, tablet, pill, lozenge, capsule, liquid dispersion, gel, aerosol, pulmonary aerosol, nasal aerosol, ointment, cream, semi-solid dosage form, and a suspension. Further, the composition may be a controlled release formulation, sustained release formulation, immediate release formulation, or any combination thereof. Further, the composition may be a transdermal delivery system.
In another embodiment, the pharmaceutical composition comprising a VIV can be formulated in a solid dosage form for oral administration, and the solid dosage form can be powders, granules, capsules, tablets or pills. In yet another embodiment, the solid dosage form can include one or more excipients such as calcium carbonate, starch, sucrose, lactose, microcrystalline cellulose or gelatin. In addition, the solid dosage form can include, in addition to the excipients, a lubricant such as talc or magnesium stearate. In some embodiments, the oral dosage form can be immediate release, or a modified release form. Modified release dosage forms include controlled or extended release, enteric release, and the like. The excipients used in the modified release dosage forms are commonly known to a person of ordinary skill in the art.
In a further embodiment, the pharmaceutical composition comprising a VIV can be formulated as a sublingual or buccal dosage form. Such dosage forms comprise sublingual tablets or solution compositions that are administered under the tongue and buccal tablets that are placed between the cheek and gum.
In yet a further embodiment, the pharmaceutical composition comprising a VIV can be formulated as a nasal dosage form. Such dosage forms of the present invention comprise solution, suspension, and gel compositions for nasal delivery.
In one embodiment, the pharmaceutical composition can be formulated in a liquid dosage form for oral administration, such as suspensions, emulsions or syrups. In other embodiments, the liquid dosage form can include, in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as humectants, sweeteners, aromatics or preservatives. In particular embodiments, the composition comprising VIV or a pharmaceutically acceptable salt thereof can be formulated to be suitable for administration to a pediatric patient.
In one embodiment, the pharmaceutical composition can be formulated in a dosage form for parenteral administration, such as sterile aqueous solutions, suspensions, emulsions, non-aqueous solutions or suppositories. In other embodiments, the non-aqueous solutions or suspensions can include propyleneglycol, polyethyleneglycol, vegetable oils such as olive oil or injectable esters such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao oil, laurin oil or glycerinated gelatin can be used.
The dosage of the pharmaceutical composition can vary depending on the patient's weight, age, gender, administration time and mode, excretion rate, and the severity of disease.
Words that are not specifically defined herein will be understood to have a meaning consistent with that as understood by persons of ordinary skill in the art.
As used herein, the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” will mean up to plus or minus 10% of the particular term.
The terms “administration of” or “administering” an active agent means providing an active agent of the invention to the subject in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically effective amount.
The terms, “expression,” “expressed,” or “encodes” refer to the process by which polynucleotides are transcribed into mRNA and/or the process by which the transcribed mRNA is subsequently being translated into peptides, polypeptides, or proteins. Expression may include splicing of the mRNA in a eukaryotic cell or other forms of post-transcriptional modification or post-translational modification.
The terms “individual,” “host,” “subject,” and “patient” are used interchangeably herein.
The term “therapeutically effective amount” refers to a sufficient quantity of the active agents of the present invention, in a suitable composition, and in a suitable dosage form to treat or prevent the symptoms, progression, or onset of the complications seen in patients suffering from a given ailment, injury, disease, or condition. The therapeutically effective amount will vary depending on the state of the patient's condition or its severity, and the age, weight, etc., of the subject to be treated. A therapeutically effective amount can vary, depending on any of a number of factors, including, e.g., the route of administration, the condition of the subject, as well as other factors understood by those in the art.
The term “treatment” or “treating” generally refers to an intervention in an attempt to alter the natural course of the subject being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects include, but are not limited to, preventing occurrence or recurrence of disease, alleviating symptoms, suppressing, diminishing or inhibiting any direct or indirect pathological consequences of the disease, ameliorating or palliating the disease state, and causing remission or improved prognosis.
As used herein, the term “VIV” refers to a vector-in-vector system for expressing at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest. The term “VIV” is used synonymously with viral delivery system, when used herein.
The following examples are given to illustrate aspects of the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. All printed publications referenced herein are specifically incorporated by reference.
This example demonstrates an exemplary VIV construct for treating an infectious disease.
In this example,
Subjects suspected of having or diagnosed as having Ebola virus can receive administrations of a therapeutically effective amount of a VIV encoding an antibody that specifically targets Ebola virus, either alone or in combination with one or more additional agents for the treatment or prevention of Ebola. VIV encoding an antibody that specifically targets Ebola virus and/or additional agents are administered orally, intranasally, intrathecally, intraocularly, intradermally, transmucosally, iontophoretically, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly according to methods known in the art or as described herein. Subjects are then evaluated daily for the presence and/or severity of signs and symptoms associated with Ebola virus, including, but not limited to, e.g., fever, fatigue, malaise, weakness, reddened eyes, joint and muscle pain, headache, nausea, vomiting, hemorrhage, and death. Treatments are maintained until such a time as one or more signs or symptoms of Ebola virus infection are ameliorated or eliminated.
It is rationally predicted that subjects suspected of having or diagnosed as having been infected with Ebola virus and receiving therapeutically effective amounts of a VIV encoding an antibody that specifically targets Ebola virus, will display reduced severity or elimination of one or more symptoms associated with Ebola virus infection. It is further rationally predicted that administration of a VIV encoding an antibody that specifically targets Ebola virus in combination with one or more additional agents will have synergistic effects.
These results will show that VIV encoding an antibody that specifically targets Ebola virus is useful in the treatment of Ebola virus.
This example demonstrates an exemplary VIV construct for preventing an infectious disease.
In this example,
Subjects suspected of having an increased risk of contracting Ebola virus can receive administrations of a prophylactically effective amount of a VIV encoding an antibody that specifically targets Ebola virus, either alone or in combination with one or more additional agents for the treatment or prevention of Ebola prior to entering an area in which risk of contracting Ebola is increased. VIV encoding an antibody that specifically targets Ebola virus and/or additional agents are administered orally, intranasally, intrathecally, intraocularly, intradermally, transmucosally, iontophoretically, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly according to methods known in the art or as described herein. Subjects are then evaluated daily for the presence and/or severity of signs and symptoms associated with Ebola virus, including, but not limited to, e.g., fever, fatigue, malaise, weakness, reddened eyes, joint and muscle pain, headache, nausea, vomiting, hemorrhage, and death. Treatments are maintained until such a time as one or more signs or symptoms of Ebola virus infection are prevented.
It is rationally predicted that subjects suspected of having or diagnosed as having been exposed to Ebola virus and receiving prophylactically effective amounts of a VIV encoding an antibody that specifically targets Ebola virus, will have a reduced risk of contracting Ebola. It is further rationally predicted that administration of VIV encoding an antibody that specifically targets Ebola virus in combination with one or more additional agents will have synergistic effects.
These results will show that VIV encoding an antibody that specifically targets Ebola virus is useful in the prevention of Ebola virus.
This example demonstrates an exemplary VIV construct for enhancing wound healing.
In this example,
Subjects with a wound (e.g., from accident, injury, or surgery) can receive administrations of a therapeutically effective amount of a VIV encoding platelet-derived growth factor (PDGF), alone or in combination with one or more additional agents for treating or sterilizing a wound. VIV PDGF and/or additional agents are administered orally, intranasally, intrathecally, intraocularly, intradermally, transmucosally, iontophoretically, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly according to methods known in the art or as described herein. Subjects are then evaluated daily to determine the status of the wound. Treatments are maintained until such a time as the wound is healed and scarring is minimized.
It is rationally predicted that subjects with a wound and receiving therapeutically effective amounts of a VIV PDGF will display enhanced wound healing. It is further rationally predicted that administration of VIV encoding PDGF in combination with one or more additional agents will have synergistic effects.
These results will show that VIV encoding PDGF is useful for enhancing wound healing.
This example demonstrates an exemplary VIV construct for treating a bone injury.
In this example,
Subjects suspected of having or diagnosed as having a bone injury can receive administrations of a therapeutically effective amount of a VIV encoding bone morphogenetic protein (BMP), alone or in combination with one or more additional agents for the treatment of the bone injury. VIV encoding BMP and/or additional agents are administered orally, intranasally, intrathecally, intraocularly, intradermally, transmucosally, iontophoretically, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly according to methods known in the art or as described herein. Subjects are then evaluated weekly for the presence and/or severity of signs and symptoms associated with the bone injury to determine the rate and strength of healing. Treatments are maintained until such a time as the bone has healed.
It is rationally predicted that subjects suspected of having or diagnosed as having a bone injury and receiving therapeutically effective amounts of a VIV encoding BMP will display reduced severity of injury and enhanced healing. It is further rationally predicted that administration of VIV encoding BMP in combination with one or more additional agents will have synergistic effects.
These results will show that VIV encoding BMP is useful in the treatment of bone injuries or diseases.
This example demonstrates an exemplary VIV construct for treating cystic fibrosis (CF).
In this example,
Subjects suspected of having or diagnosed as having (CF) can receive administrations of a therapeutically effective amount of a VIV encoding cystic fibrosis transmembrane conductance regulator (CFTR), alone or in combination with one or more additional agents for the treatment of CF. VIV encoding CFTR and/or additional agents are administered orally, intranasally, intrathecally, intraocularly, intradermally, transmucosally, iontophoretically, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly according to methods known in the art or as described herein. Subjects are then evaluated weekly for the presence and/or severity of signs and symptoms associated with CF, including, but not limited to, e.g., poor growth, persistent cough, thick sputum and mucus, wheezing, breathlessness, decreased ability to exercise, repeated lung infections, inflamed nasal passage, greasy stools, intestinal blockage, and poor weight gain. Treatments are maintained until such a time as one or more signs or symptoms of CF are ameliorated or eliminated.
It is rationally predicted that subjects suspected of having or diagnosed as having CF and receiving therapeutically effective amounts of a VIV encoding CFTR will display reduced severity or elimination of one or more symptoms associated with CF. It is further rationally predicted that administration of VIV encoding CFTR in combination with one or more additional agents will have synergistic effects.
These results will show that VIV encoding CFTR is useful in the treatment of CF.
A vector according to
A lentiviral vector was obtained from System Biosciences, Inc. The plasmid was cleaved with BamHI and EcoRI enzymes, and mixed with excess amplified green fluorescent protein gene sequences in a 1:3 ratio of insert to vector.
Enzymatic activity was then stopped by heat inactivation at 70 degrees Celsius for 20 minutes. The above mixture was cooled to room temperature to allow annealing.
The annealing reactions were performed with bacteriophage T4 DNA ligase for 30 minutes at room temperature. 2.5 microliters of the resulting ligation mix were added to 25 microliters of STBL3 competent bacterial cells.
Transfection was then carried out by a brief (1 minute) heat-shock at 42 degrees Celsius.
Bacterial cells were streaked onto agar plates containing ampicillin to obtain bacterial cultures. These cultures were expanded in Luria broth.
To check for insertion of amplified green fluorescent protein gene sequences into the lentivirus vector packaging plasmid, DNA was extracted from the above bacterial cultures and purified by standard methods. Purified DNA was digested with the same endonucleases used to make the construct. Fragment lengths were analyzed by agarose gel electrophoresis, and the amplified green fluorescent protein gene sequences were verified by DNA sequencing using specific primers obtained from Eurofins MWG Operon LLC.
Lentivirus vector stocks were produced as follows. At least two lentiviral packaging plasmids plus the cargo plasmid were co-transfected into HEK cells where viral genes and genomic RNA are expressed, assembled into integrase-deficient lentivirus particles, and released into the culture medium. Cell-free supernatants were produced and collected during the interval of 3-10 days after transfection. Lentivirus particles were purified by standard procedures including a combination of methods that could include centrifugation, transient flow filtration, size exclusion chromatography, size exclusion filtration or ion exchange chromatography. The concentration and biological activity (transducing units per ml) for each stock were determined.
Mammalian cells, including 293T cells, were used to test for lentivirus-derived episome formation, copy number and expression. The 293T cells were transduced with integrase deficient lentivirus particles at a multiplicity of infection ranging from 1 to 10 in the presence of polybrene. Unabsorbed virus was removed by washing cells 3 hours after application, and cells were cultured for 3 days. Cells were observed in a fluorescence microscope and cells expressing GFP were counted. Untransduced 293 T cells were used as a negative control. Data was reported as GFP-positive cells per 100 viable cells in culture. A minimum of 300 cells were counted per microscope field and 5-10 fields were counted for each replicate experiment. Four independent transduction experiments comprising one negative control and three replicate experiments were performed to determine the frequency of transduced cells. The data is depicted in
Referring to
293T cells can be transduced with Vector 19 at a multiplicity of infection ranging from between 1 and 20 transducing units per cell. 3 hours later, cells are washed with medium to remove unadsorbed virions and returned to culture. 12-24 hours after transduction, cells are treated with at least one dosage of a compound that can induce the inducible promoter. Upon addition of a compound that can induce the inducible promoter, E1 and E2 mRNA are transcribed from the episome and combine and assemble on the Locus Control Region Fragment 2 (LCR/F2) (SEQ ID NO: 3) to trigger DNA replication. Lentivirus-derived episomes decay starting approximately 24-36 hours after the cessation of promoter induction. Protein products from the cargo in Vector 19 are measured by analytical flow cytometry.
To determine the effect of E1 and E2 in expressing cargo, 293T cells were transduced with a D64V integrase-deficient lentiviral vector (i.e., vector in
Notably, in reference to
After 24 hours, cells were transfected with plasmids containing HPV16 E1 (SEQ ID NO: 6) and E2 (SEQ ID NO: 7) with Lipofectamine 2000. After 2 days, mCherry expression was analyzed by FACS. The results for these experiments are depicted in
To contrast with the above experiments wherein E1 and E2 were introduced through plasmids, a second set of experiments were performed as described below. Briefly, 293T cells were transduced with a D64V integrase-deficient lentiviral vector expressing mCherry and the full length HPV16 long control region (LCR) (SEQ ID NO: 1) or a shorter Fragment 1 (SEQ ID NO: 2) based on the generalized vector shown in
The data detailed in this Example demonstrate that when E1 and E2 are expressed via lentiviral-mediated expression, there was stronger expression and thus more activation of HPV ori (LCR) full-length and fragments.
Secondly, the data from this Example demonstrates that there is a difference in HPV ori activation depending on the size of the LCR region. For example, with reference to
As mentioned herein, VEGF can be selected to be a “cargo” region for treating, among other things, a bone injury. To further analyze the level of VEGF expression, 293T cells were transduced with a D64V integrase-deficient lentiviral vector containing a human cDNA for VEGF (SEQ ID NO: 26) and Fragment 1 (SEQ ID NO: 2) of the HPV16 long control region (LCR) (see:
In a manner similar to the mCherry results from Example 8 above, the results demonstrate that there was a difference in HPV ori activation depending on the size of the LCR region. As shown in
Using standard molecular biology techniques (e.g., Sambrook; Molecular Cloning: A Laboratory Manual, 4th Ed.) as well as the techniques described herein, a series of lentiviral vectors containing the HPV LCRs and E1 and E2 were developed as described in greater detail below. These vectors are also depicted in
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Still referring to
The linear vectors detailed herein circularize intracellularly as shown, for example in
In the experiments detailed herein, integrase-deficient lentiviral vector copy number was regulated by a combination of utilizing Vector 20 in combination with Vector 21 or Vector 22 or Vector 23 or Vector 24. Alternately, integrase-deficient lentiviral vector copy number was regulated by a combination of utilizing Vector 20 in combination with Vector 25 or Vector 26.
As discussed herein, the LCR portion of the vectors detailed herein can be and were modified through the use of fragments such as Fragment 1 (SEQ ID NO: 2), Fragment 2 (SEQ ID NO: 3), Fragment 3 (SEQ ID NO: 4); and Fragment 4 (SEQ ID NO: 5).
The genomic organization of the LCR and the fragments described herein is depicted in
To test vectors containing the various LCR fragments detailed herein, 293T cells were transduced with D64V integrase-deficient lentiviral vectors containing either full length HPV16 long control region (LCR) or Fragment 1 (SEQ ID NO: 2), Fragment 2 (SEQ ID NO: 3), Fragment 3 (SEQ ID NO: 4), and Fragment 4 (SEQ ID NO: 5) as described herein (see, for e.g.,
After 24 hours, cells were transfected with plasmids containing HPV16 E1 (SEQ ID NO: 6) and E2 (SEQ ID NO: 7) with Lipofectamine 2000. After 2 days, DNA was extracted for analysis by qPCR. Primers represented by SEQ ID NO: 11 and SEQ ID NO: 12, which are specific for the episomal form of the lentiviral vector were used to determine the episomal copy number. Notably, this primer set amplified only 1- and 2-LTR episomes. The data for this Example is depicted in
In a separate set of related experiments, analysis was carried out for mCherry expression from integrase-deficient lentiviral vectors containing the HPV LCR and 3′ fragments thereof. Briefly, 293T cells were transduced with D64V integrase-deficient lentiviral vectors expressing mCherry and either full length HPV16 long control region (LCR) or Fragment 1 (SEQ ID NO: 2), Fragment 2 (SEQ ID NO: 3), Fragment 3 (SEQ ID NO: 4), and Fragment 4 (SEQ ID NO: 5). At the same time, cells were transduced with lentivirus expressing HPV16 E1 (SEQ ID NO: 6) and E2 (SEQ ID NO: 7). After 2 days, mCherry expression was analyzed by FACS.
As shown in
In a separate set of related experiments, 293T cells were transduced with a D64V integrase-deficient lentiviral vector expressing mCherry and the full-length HPV16 long control region identified previously as SEQ ID NO: 1. At the same time, cells were transduced with lentivirus expressing HPV16 E1-T2A-E2 (SEQ ID NO: 10) from a single vector (see: Vector 25 from
In a separate set of related experiments, an analysis was conducted of mCherry expression using integrase-deficient lentiviral vectors containing HPV LCR following the addition of E1, E1-C, and E2-11. Briefly, 293T cells were transduced with a D64V integrase-deficient lentiviral vector expressing mCherry and HPV16 LCR (SEQ ID NO: 1) or Fragment 1 (SEQ ID NO: 2). At the same time, cells were transduced with HPV16 E1 (i.e., Vector 21 in
As mentioned herein, one of the features of the disclosed system is the usefulness of the disclosed system to express an antibody. In a series of representative experiments detailed herein, an anti-HER2 antibody was expressed using the lentiviral vector system. Briefly, 293T cells were infected with a D64 integrase-deficient lentiviral vector (i.e., Vector 20) containing an antibody sequence against HER2 (SEQ ID NO: 13) and the HPV LCR (SEQ ID NO: 1) sequence.
At the same time, cells were infected with lentiviral vectors containing E1 (SEQ ID NO: 6) and E2 (SEQ ID NO: 7). After 3 days, cell culture media was collected. Antibody was purified from the media using Protein A/G agarose beads. An immunoblot was performed using a sheep anti-human antibody (Thermo Scientific). Antibody production was increased with the addition of E1 and E2 as shown in
Further, as shown in
After 24 hours, cells were infected with lentiviral vectors containing E1 (SEQ ID NO: 6) and E2 (SEQ ID NO: 7). After 3 days, cell lysate and cell culture media was collected. Antibody was purified from media using Protein A/G agarose beads and extracted from cells by cell lysis. An immunoblot was performed using a sheep anti-human antibody (Thermo Scientific) and an anti-actin (Sigma) antibody for a protein loading control for cell lysate. Antibody production was increased in both cell lysate and media with the addition of E1 and E2, as shown in
As mentioned herein, one of the features of the disclosed system is the usefulness of the disclosed system to express a microRNA. As a non-limiting example, constructs were designed to express microRNA for CCR5 based on the SEQ ID NO: 15.
Briefly, HeLa cells expressing CCR5 were infected with a D64 integrase-deficient lentiviral vector (i.e., Vector 20) containing a microRNA sequence against CCR5 (SEQ ID NO: 15) and the full-length HPV LCR (SEQ ID NO: 1) sequence. At the same time, cells were infected with lentiviral vectors containing E1 and E2. After 3 days, cells were collected and analyzed for CCR5 expression by FACS analysis with an anti-CCR5 APC-conjugated antibody. As shown in
In related experiments, a D64 integrase-deficient lentiviral vector containing a microRNA sequence against CCR5 and the Fragment 2 (SEQ ID NO: 3) LCR sequence were utilized. As shown in
Referring in more detail to
As mentioned herein, initiator proteins such as E1 (SEQ ID NO: 6) and E2 (SEQ ID NO: 7) are used to augment the effectiveness of the systems described herein. An alternate initiator protein that can be used in the current system is EBNA-1 (SEQ ID NO: 32). Accordingly in a series of experiments, 293T cells were transduced with a D64V integrase-deficient lentiviral vector (i.e., Vector 27) expressing GFP and the Epstein-Barr Virus (EBV) OriP sequence (SEQ ID NO: 31).
After 24 hours, cells were transfected with a plasmid containing EBV EBNA-1 (SEQ ID NO: 32) with Lipofectamine 2000. After 2 days, GFP expression was analyzed by FACS. As shown in representative data in
Based on the data detailed herein, varied levels of expression, as determined by episome copies per cell, can be attributed to the various LCR fragments tested herein. As shown in
Referring to both
As summarized in
Moving to
As detailed in
The following sequences are referred to herein:
While certain preferred embodiments of the present invention have been described and specifically exemplified herein, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention.
This application is a U.S. national phase filing under 35 U.S.C. § 371 of PCT/US2016/066185 filed on Dec. 12, 2016, entitled “NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO,” which claims priority to U.S. Provisional Patent Application No. 62/347,552 filed on Jun. 8, 2016 entitled “NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS OF USE THEREOF” and U.S. Provisional Patent Application No. 62/431,760 filed on Dec. 8, 2016 entitled “NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO,” the disclosures of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2016/066185 | 12/12/2016 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2017/213697 | 12/14/2017 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 5668255 | Murphy | Sep 1997 | A |
| 5674703 | Woo et al. | Oct 1997 | A |
| 6156514 | Acevedo et al. | Dec 2000 | A |
| 6399383 | Apt et al. | Jun 2002 | B1 |
| 6635472 | Lauermann | Oct 2003 | B1 |
| 7371542 | Ivanova et al. | May 2008 | B2 |
| 8124752 | Bumcrot et al. | Feb 2012 | B2 |
| 8287857 | Dudley et al. | Oct 2012 | B2 |
| 8546555 | Gould-Fogerite et al. | Oct 2013 | B2 |
| 8993532 | Hannon et al. | Mar 2015 | B2 |
| 9522176 | DeRosa et al. | Dec 2016 | B2 |
| 9527904 | Balazs | Dec 2016 | B2 |
| 9834790 | Pauza et al. | Dec 2017 | B1 |
| 9834791 | Zhang | Dec 2017 | B2 |
| 9914938 | Pauza et al. | Mar 2018 | B2 |
| 10023880 | Pauza et al. | Jul 2018 | B2 |
| 10036038 | Pauza et al. | Jul 2018 | B2 |
| 10036040 | Pauza et al. | Jul 2018 | B2 |
| 10137144 | Pauza et al. | Nov 2018 | B2 |
| 10208295 | DeRosa et al. | Feb 2019 | B2 |
| 10233464 | Pauza et al. | Mar 2019 | B2 |
| 20020168345 | Dong et al. | Nov 2002 | A1 |
| 20030013196 | Engleman et al. | Jan 2003 | A1 |
| 20030096787 | Perridcaudet et al. | May 2003 | A1 |
| 20030119770 | Lai | Jun 2003 | A1 |
| 20030138444 | Zavitz et al. | Jul 2003 | A1 |
| 20040142416 | Laipis et al. | Jul 2004 | A1 |
| 20040161412 | Penn et al. | Aug 2004 | A1 |
| 20040192629 | Xu et al. | Sep 2004 | A1 |
| 20040214158 | Sethi et al. | Oct 2004 | A1 |
| 20040248296 | Beresford et al. | Dec 2004 | A1 |
| 20050019927 | Markus et al. | Jan 2005 | A1 |
| 20050138677 | Pfister et al. | Jun 2005 | A1 |
| 20060057553 | Aguilar-Cordova | Mar 2006 | A1 |
| 20060183230 | Silla et al. | Aug 2006 | A1 |
| 20060246520 | Champagne et al. | Nov 2006 | A1 |
| 20070026521 | Colosi | Feb 2007 | A1 |
| 20070141679 | Sodroski | Jun 2007 | A1 |
| 20070203333 | McSwiggen et al. | Aug 2007 | A1 |
| 20080003225 | Vie et al. | Jan 2008 | A1 |
| 20080003682 | Lois-Caballe et al. | Jan 2008 | A1 |
| 20080039413 | Morris et al. | Feb 2008 | A1 |
| 20080131940 | Chiu | Jun 2008 | A1 |
| 20080153737 | Lieberman et al. | Jun 2008 | A1 |
| 20080199961 | Rasko et al. | Aug 2008 | A1 |
| 20080227736 | Chen et al. | Sep 2008 | A1 |
| 20080293142 | Liu et al. | Nov 2008 | A1 |
| 20090017543 | Wilkes et al. | Jan 2009 | A1 |
| 20090148936 | Stout et al. | Jun 2009 | A1 |
| 20090304688 | Fournie et al. | Dec 2009 | A1 |
| 20100017911 | Dawson et al. | Jan 2010 | A1 |
| 20100069372 | Kazantsev | Mar 2010 | A1 |
| 20100119511 | Wang et al. | May 2010 | A1 |
| 20100120155 | Brennan et al. | May 2010 | A1 |
| 20100286166 | Pey Rodriguez et al. | Nov 2010 | A1 |
| 20100316676 | Sanders | Dec 2010 | A1 |
| 20110008803 | Stockwell et al. | Jan 2011 | A1 |
| 20110177155 | Peer et al. | Jul 2011 | A1 |
| 20110207226 | Ni et al. | Aug 2011 | A1 |
| 20120053223 | Benkirane et al. | Jan 2012 | A1 |
| 20120027725 | Galvin | Feb 2012 | A1 |
| 20120114607 | Lai et al. | May 2012 | A1 |
| 20120034197 | Young et al. | Aug 2012 | A1 |
| 20120201794 | Chen et al. | Sep 2012 | A1 |
| 20130078276 | Robinson et al. | Mar 2013 | A1 |
| 20130090371 | Lu et al. | Apr 2013 | A1 |
| 20130142766 | Dodo et al. | Jun 2013 | A1 |
| 20130211380 | Aquino et al. | Aug 2013 | A1 |
| 20140155468 | Gregory et al. | Jun 2014 | A1 |
| 20140162894 | Hatchwell et al. | Jun 2014 | A1 |
| 20140178340 | Robbins et al. | Jun 2014 | A1 |
| 20140234958 | Kashara et al. | Aug 2014 | A1 |
| 20140248277 | Hoffman et al. | Sep 2014 | A1 |
| 20140336245 | Mingozzi et al. | Nov 2014 | A1 |
| 20150010578 | Balazs et al. | Jan 2015 | A1 |
| 20150018539 | Fellmann | Jan 2015 | A1 |
| 20150126580 | DePinho et al. | May 2015 | A1 |
| 20150132255 | Sorensen et al. | May 2015 | A1 |
| 20150176006 | Krause et al. | Jun 2015 | A1 |
| 20160060707 | Goldenberg et al. | Mar 2016 | A1 |
| 20160243169 | Chen et al. | Aug 2016 | A1 |
| 20160289681 | Rossi | Oct 2016 | A1 |
| 20170015976 | Nelson | Jan 2017 | A1 |
| 20170028036 | Mingozzi et al. | Feb 2017 | A1 |
| 20170037369 | Ramsborg et al. | Feb 2017 | A1 |
| 20170335344 | Pauza et al. | Nov 2017 | A1 |
| 20180010147 | Pauza | Jan 2018 | A1 |
| 20180142257 | Pauza | May 2018 | A1 |
| 20180142258 | Pauza | May 2018 | A1 |
| 20180161455 | Pauza | Jun 2018 | A1 |
| 20180177866 | Pauza | Jun 2018 | A1 |
| 20180195046 | Deng | Jul 2018 | A1 |
| 20180195050 | Szalay | Jul 2018 | A1 |
| 20180256624 | Pauza | Sep 2018 | A1 |
| 20180305716 | Pauza | Oct 2018 | A1 |
| 20180355032 | Roberts | Dec 2018 | A1 |
| 20190046633 | Pauza et al. | Feb 2019 | A1 |
| 20190062786 | Pauza et al. | Feb 2019 | A1 |
| 20190078096 | Lahusen et al. | Mar 2019 | A1 |
| 20190083523 | Pauza | Mar 2019 | A1 |
| 20190388456 | Pauza et al. | Dec 2019 | A1 |
| 20200063161 | Pauza | Feb 2020 | A1 |
| 20200087682 | Lahusen et al. | Mar 2020 | A1 |
| 20200109417 | Pauza et al. | Apr 2020 | A1 |
| 20200155590 | Zhennan | May 2020 | A1 |
| 20200181645 | Pauza | Jun 2020 | A1 |
| 20200318081 | Lahusen et al. | Oct 2020 | A1 |
| 20210047644 | Lahusen | Feb 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 2515 | Mar 2019 | BR |
| 101516365 | Aug 2009 | CN |
| 101679466 | Mar 2010 | CN |
| 101805750 | Aug 2010 | CN |
| 103184224 | Jul 2013 | CN |
| 105112370 | Dec 2015 | CN |
| 108883100 | Nov 2018 | CN |
| 1647595 | Apr 2006 | EP |
| 3402483 | Nov 2018 | EP |
| 3413926 | Dec 2018 | EP |
| 3426777 | Jan 2019 | EP |
| 3468617 | Apr 2019 | EP |
| 3468618 | Apr 2019 | EP |
| 3481418 | May 2019 | EP |
| 3481435 | May 2019 | EP |
| 201947000153 | Feb 2019 | IN |
| 2002506652 | Mar 2002 | JP |
| 2007-527240 | Sep 2007 | JP |
| 2008518591 | Jun 2008 | JP |
| 2008-538174 | Oct 2008 | JP |
| 2012508591 | Apr 2012 | JP |
| 2013-5300152 | Jul 2013 | JP |
| 2015-518838 | Jul 2015 | JP |
| 2016-502404 | Jan 2016 | JP |
| 199947691 | Sep 1999 | WO |
| 2002020554 | Mar 2002 | WO |
| 2003093436 | Nov 2003 | WO |
| 2004053137 | Jun 2004 | WO |
| 2005028634 | Mar 2005 | WO |
| 2005033282 | Apr 2005 | WO |
| 2006039721 | Apr 2006 | WO |
| 2006048215 | May 2006 | WO |
| 2007000668 | Jan 2007 | WO |
| 2007015122 | Feb 2007 | WO |
| 2007132292 | Nov 2007 | WO |
| 2007133674 | Nov 2007 | WO |
| WO2008025025 | Feb 2008 | WO |
| 2008090185 | Jul 2008 | WO |
| 2009100928 | Aug 2009 | WO |
| 2009147445 | Dec 2009 | WO |
| 2010051521 | May 2010 | WO |
| 2010117974 | Oct 2010 | WO |
| 2010127166 | Nov 2010 | WO |
| 2011008348 | Jan 2011 | WO |
| 2011071476 | Jun 2011 | WO |
| 2011119942 | Sep 2011 | WO |
| WO 2011119942 | Sep 2011 | WO |
| WO-2011119942 | Sep 2011 | WO |
| 2012048303 | Apr 2012 | WO |
| 2012061075 | May 2012 | WO |
| WO2012145624 | Oct 2012 | WO |
| 2013096455 | Jun 2013 | WO |
| 2014016817 | Jan 2014 | WO |
| 2014117050 | Jul 2014 | WO |
| 2014187881 | Nov 2014 | WO |
| 2015017755 | Feb 2015 | WO |
| 2015042308 | Mar 2015 | WO |
| 2015061491 | Apr 2015 | WO |
| 2015078999 | Jun 2015 | WO |
| WO 2015078999 | Jun 2015 | WO |
| 2015086854 | Aug 2015 | WO |
| WO2015164759 | Oct 2015 | WO |
| 2016046234 | Mar 2016 | WO |
| 2016061232 | Apr 2016 | WO |
| WO2016061232 | Apr 2016 | WO |
| 2016069716 | May 2016 | WO |
| 2016200997 | Jul 2016 | WO |
| 2016189159 | Dec 2016 | WO |
| 2017007994 | Jan 2017 | WO |
| 20170068077 | Apr 2017 | WO |
| 2017100551 | Jun 2017 | WO |
| 2017123918 | Jul 2017 | WO |
| 2017139065 | Aug 2017 | WO |
| 2017156311 | Sep 2017 | WO |
| 20170173453 | Oct 2017 | WO |
| 2017213697 | Dec 2017 | WO |
| 2017214327 | Dec 2017 | WO |
| 2018009246 | Jan 2018 | WO |
| 2018009847 | Jan 2018 | WO |
| 2018017882 | Jan 2018 | WO |
| 2018126112 | Jul 2018 | WO |
| 2018129540 | Jul 2018 | WO |
| 20180148443 | Aug 2018 | WO |
| 2018187231 | Oct 2018 | WO |
| 2018232359 | Dec 2018 | WO |
| WO2019070674 | Apr 2019 | WO |
| 2020097049 | May 2020 | WO |
| 2020243717 | Dec 2020 | WO |
| Entry |
|---|
| Bergvall et al. The E1 proteins. Virology 445:35-56, (Year: 2013). |
| McBride, A. The papillomavirus E2 proteins. Virology 445:57-79, (Year: 2013). |
| Chiang C-M et al. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. PNAS 89:5799-5803, (Year: 1992). |
| Krajinovic et al. Sequencing data on the long control region of human papillomavirus type 16. J. General Virology 72:2573-2576, (Year: 1991). |
| Seedorg et al. Human papillomavirus type 16 DNA sequence. Virology 145:181-185, (Year: 1985). |
| Oh et al. “Lentiviral Vector Design Using Alternative RNA Export Elements,” Retrovirology, vol. 4:38, pp. 1-10, (2007). |
| Pallikkuth et al., “Human Immunodeficiency Virus (HIV) gag Anti-Specific T-Helper and Granule-Dependent CD8 T-Cell Activities in Exposed but Uninfected Heterosexual Partners of HIV Type 1-Infected Individuals in North India,” Clinical and Vaccine Immunology, vol. 14(9) pp. 1196-1202, (2007). |
| Vargas, J. Jr. et al., “Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy,” Antiviral Res. Dec. 2008 vol. 80 No. 3, pp. 288-294. |
| Thompson et al., “Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway,” Blood, Jan. 15, 2006, vol. 107, pp. 651-654. |
| Gober et al., “Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells,” J. of Experimental Med., Jan. 20, 2003, vol. 197, pp. 163-168. |
| Goepfert, et al., “Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-2 Virus-Like Particles,” J. Infectious Diseases, Jul. 1, 2014, vol. 210, pp. 99-110. |
| Tebas, P. et al, “Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV,” Blood, 2013, vol. 121, No. 9, pp. 1524-1533. |
| Tebas, p. et al., “Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV,” The New England Journal of Medicine, vol. 370 (10), pp. 901-910, Mar. 6, 2014. |
| Li et al., “Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by Vy2Vδ2 T Cells,” J. of Immunology, 2009, vol. 182, pp. 8118-8124. |
| Wang et al., “Indirect Stimulation of Human Vy2Vδ2 T Cells through Alterations in Isoprenoid Metabolism,” J. of Immunology, vol. 187 pp. 5099-5113, (Nov. 15, 2011). |
| Stunkel et al., “The Chromatin Structure of the Long Control Region of Human Papillomavirus Type 16 Repress Viral Oncoprotein Expression,” Journal of Virology, vol. 73, No. 3, pp. 1918-1930 (Mar. 1999). |
| Lu et al., “Anti-sense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance,” Journal of Virology, vol. 79, No. 13, pp. 7079-7088 (Jul. 2004). |
| Dieli et al., “Targeting Human yõ T Cells with Zoledronate and lnterleukin-2 for lmmunotherapy of Hormone-Refractory Prostate Cancer,” Europe PMC Funders Group, Cancer Research, vol. 67(15), pp. 7450-1451, (Aug. 1, 2007). |
| Moser et al., “yδ T cells: novel initiators of adaptive immunity,” Immunological Reviews, vol. 215, pp. 89-102 (Feb. 2, 2007). |
| Capietto, A. H. et al., “Stimulated yδ T Cells Increase the in Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer,” J Immunology, vol. 187(2), pp. 1031-1038, (2011). |
| Chen, Z. and M. S. Freedman, “CD16+ yδ T Cells Mediate Antibody Dependent Cellular Cytotoxicity: Potential Mechanism in the Pathogenesis of Multiple Sclerosis,” Clin Immunology, vol. 128(2), pp. 219-227, (2008). |
| Couzi, L. et al., “Antibody-Dependent Anti-Cytomegalovirus Activity of Human yδ T Cells Expressing CD16 (FcyRIIIa),” Blood, vol. 119(6), pp. 1418-1427, (2012). |
| Fisher, J. P. et al., “Effective Combination Treatment of GD2-Expressing Neuroblastoma and Ewing's Sarcoma Using Anti-GD2 ch14.18/CHO Antibody with Vy9Vδ2+ yδT Cells,” OncoImmunology, vol. 5(1), pp. e1025194, (2016). |
| Gertner-Dardenne, J. et al., “Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies,” Blood 113(20): 4875-4884, (2009). |
| Poonia, B. and C. D. Pauza, “Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity,” Cytotherapy 14(2): 173-181, (2012). |
| Schiller, C. B. et al., “CD19-Specific Triplebody SPM-1 Engages NK and yδ T Cells for Rapid and Efficient Lysis of Malignant B-Lymphoid Cells,” Oncotarget, vol. 7(50), pp. 83392-83408, (2016). |
| Tokuyama, H. et al., “Vy9Vδ2 T Cell Cytotoxicity Against Tumor Cells is Enhanced by Monoclonal Antibody Drugs—Rituximab and Trastuzumab,” Int J Cancer, vol. 122(11), pp. 2526-2534, (2008). |
| Zufferey et al., “Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery,” Journal of Virology, vol. 72(12), pp. 9873-9880, (1998). |
| Ostertag et al., “Brain Tumor Eradication and Prolonged Survival from Intratumoral Conversion of 5-Fluorocytosine to 5-fluorouracil Using a Nonlytic Retroviral Replicating Vector,” Neoro-Oncology 14(2), pp. 145-159, Feb. 2012. |
| Twitty et al., “Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types,” Human Gene Therapy Methods, 27(1), pp. 17-31, Feb. 1, 2016. |
| Charron et al., “Dominant-Negative Interference in the Pahenu2 Mouse Model of PKU: Effectiveness of Vectors Expressing Either Modified Forms of Phenylalanine Hydroxylase (PAH) or Ribozymes Plus a Hardened PAH mRNA,” Molecular Therapy, vol. 11, pp. S163-S164, (2005). |
| Fusetti, et al., “Structure of Tetrameric Human Phenylalanine Hydroxylase and Its Implications for Phenylketonuria,” J. Bio. Chem., vol. 273, No. 27, pp. 16962-16967 (1998). |
| Hafid et al., “Phenylketonuria: A Review of Current and Future Treatments,” Translational Pediatrics, vol. 4(4), pp. 304-317, (2015). |
| Blau et al., “Phenylketonuria,” The Lancet, vol. 376(9750), pp. 1417-1427, (2010). |
| Chandler et al., “Vector Design Influences Hepatic Genotoxicity After Adeno-Associated Virus Gene Therapy,” Journal of Clinical Investigation, vol. 125(2), pp. 870-880, (2015). |
| Christophersen et al., “A Technique of Transumbilical Portal Vein Catheterization in Adults,” The Archives of Surgery, vol. 95(6), pp. 960-963, (1967). (Abstract Only). |
| Bartholome, “Genetics and Biochemistry of the Phenylketonuria-Present State,” Human Genetics, vol. 51(3), pp. 241-245, (1979). |
| Donsante et al., “AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma,” Science, vol. 317(5837, p. 477, (2007). |
| Eisensmith et al., “Multiple Origins for Phenylketonuria in Europe,” American Journal of Human Genetics, vol. 51(6), pp. 1355-1365, (1992). |
| Fisher et al., “The Inhibition of Phenylalanine and Tyrosine Hydroxylases by High Oxygen Levels,” Journal of Neurochemistry, vol. 19(5), pp. 1359-1365, (1972). (Abstract Only). |
| Grisch-Chan et al., “Low-Dose Gene Therapy for Murine PKU Using Episomal Naked DNA Vectors Expressing PAH from Its Endogenous Liver Promoter,” Molecular Therapy Nucleic Acids, vol. 7, pp. 339-349, (2017). |
| Guldberg et al., “Aberrant Phenylalanine Metabolism in Phenylketonuria Heterozygotes,” Journal of Inherited Metabolic Disease, vol. 21(4), pp. 365-372, (1998). |
| Kaufman et al., “A Model of Human Phenylalanine Metabolism in Normal Subjects and in Phenylketonuric Patients,” Proceedings of the National Academy of Sciences USA, vol. 96(6), pp. 3160-3164, (1999). |
| Kaufman et al., “Phenylalanine Hydroxylase Activity in Liver Biopsies from Hyperphenylalaninemia Heterozygotes: Deviation from Proportionality with Gene Dosage,” Pediatric Research, vol. 9(8), pp. 632-634, (1975). |
| Longo et al., “Single-Dose, Subcutaneous Recombinant Phenylalanine Ammonia Lyase Conjugated with Polyethylene Glycol in Adult Patients with Phenylketonuria: An Open-Label, Multicentre, Phase 1 Dose-Escalation Trial,” The Lancet, vol. 384(9937), pp. 37-44, (2014). |
| Mochizuki et al., “Long-Term Correction of Hyperphenylalaninemia by AAV-Mediated Gene Transfer Leads to Behavioral Recovery in Phenylketonuria Mice,” Gene Therapy, vol. 11(13), pp. 1081-1086, (2004). |
| Nault et al., “Adeno-Associated Virus Type 2 as an Oncogenic Virus in Human Hepatocellular Carcinoma,” Molecular & Cellular Oncology, vol. 3(2), p. e1095271, (2016). |
| Oh et al., “Reversal of Gene Expression Profile in the Phenylketonuria Mouse Model After Adeno-Associated Virus Vector-Mediated Gene Therapy,” Molecular Genetics and Metabolism, vol. 86(Supp. 1), pp. S124-S132, (2005). |
| Oh et al., “Long-Term Enzymatic and Phenotypic Correction in the Phenylketonuria Mouse Model by Adeno-Associated Virus Vector-Mediated Gene Transfer,” Pediatric Research, vol. 56(2), pp. 278-284, (2004). |
| Pan et al., “Biodistribution and Toxicity Studies of VSVG-Pseudotyped Lentiviral Vector After Intravenous Administration in Mice with the Observation of in Vivo Transduction of Bone Marrow,” Molecular Therapy, vol. 6(1), pp. 19-29, (2002). |
| Shedlovsky et al., “Mouse Models of Human Phenylketonuria,” Genetics, vol. 134(4), pp. 1205-1210, (1993). |
| Yagi et al., “Complete Restoration of Phenylalanine Oxidation in Phenylketonuria Mouse by a Self-Complementary Adeno-Associated Virus Vector,” Journal of Gene Medicine, vol. 13(2), pp. 114-122, (2011). |
| Yano et al., “Evaluation of Tetrahydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotransmitters,” PLoS One, vol. 11(8), p. e0160892, (2016). |
| Mason et al., “Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy,” Journal of Virology, vol. 83(3), pp. 1501-1510, (2009). |
| Blick et al., “Cyclophosphamide Enhances SB-728-T Engraftment to Levels Associated with HIV-RNA Control,” CROI Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, p. 141, (2014), (Abstract Only). |
| De Rose et al., “Safety, Immunogenicity and Efficacy of Peptide-Pulsed Cellular Immunotherapy in Macaques,” Journal of Medical Primatology, vol. 27(2), pp. 69-78, (2008). |
| Smith et al., “Developments in HIV-1 Immunotherapy and therapeutic Vaccination,” F1000Prime Reports, vol. 6, p. 42, (2014). |
| Charron, “Gene Therapy for Phenylketonuria: Dominant-Negative Interference in a Recessive Disease,” Dissertation, University of Florida 2005, http://etd.fcla.edu/UF/UFE0011392/charron_c.pdf>, (retrieved Jul. 26, 2018) (2005). |
| Ding et al., “Administration-Route and Gender-Independent Longterm Therapeutic Correction of Phenylketonuria (PKU) in a Mouse Model by Recombinant Adeno-Associated Virus 8 Pseudotyped Vector-Mediated Gene Transfer,” Gene Therapy, vol. 13, pp. 583-587, (Dec. 1, 2005). |
| Nowacki et al., “The PAH Mutation Analysis Consortium Database: Update 1996,” Nucleic Acid Research, vol. 25(1), pp. 139-142, (Jan. 1, 1997). |
| Condiotti et al., “Prolonged Liver-Specific Transgene Expression by a Non-Primate Lentiviral Vector,” Biochemical and Biophysical Research Communications, vol. 320(3), pp. 998-1006, (Jul. 30, 2004). |
| Wang et al., “Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human Vg2Vd2 T Cells,” Journal of Immunology, vol. 191(3), pp. 1029-1042, (Jul. 5, 2013). |
| Jiang et al., “A Novel EST-Derived RNAi Screen Reveals a Critical Role for Farnesyl Diphosphate Synthase in Beta2-Adrenergic Receptor Internalization and Down-Regulation,” FASEB Journal, vol. 26(5), pp. 1-13, (Jan. 25, 2012). |
| Miettinen et al., “Mevalonate Pathway Regulates Cell Size Homeostasis and Proteostasis Through Autophagy,” Cell Reports, vol. 13(11), pp. 2610-2620, (Dec. 2015). |
| Tolmachov, “Designing Lentiviral Gene Vectors,” Viral Gene Therapy, Chapter 13, pp. 263-284, (2011). |
| Tracey, “Human DNA Sequence from Clone RP1-288M22 on Chromosome 6q 12-13,” Complete Sequence, National Center for Biotechnology. GenBank Entry. Retrieved from the internet: <https://www.ncbi.nlm.nih.gov/nucleotide/AL035467.23?report=genbank&log$=nucltop&blast_rank=1&RID=UUD4GX2D014>; pp. 1-34, (Jan. 24, 2013). |
| Gorziglia et al., “Elimination of Both E1 and E2A from Adenovirus Vectors Further Improves Prospects for In Vivo Human gene Therapy,” Journal of Virology, vol. 70(6), pp. 4173-4178, (1996). |
| Vargas et al., “Novel Integrase-Defective Lentiviral Episomal Vectors for Gene Transfer,” Human Gene Therapy, vol. 15(4), pp. 361-372, (Apr. 2004). |
| Wendelburg et al., “An Enhanced EBNA1 Variant with reduced IR3 Domain for Long-Term Episomal Maintenance and Transgene Expression of ORIP-Based Plasmids in Human Cells,” Gene Therapy, vol. 5, pp. 1389-1399, (Oct. 1998). |
| Westerhout et al., “A Conditionally Replicating HIV-Based Vector that Stably Expresses an Antiviral shRNA Against HIV-1 Replication,” Molecular Therapy: The Journal of the American Society of Gene Therapy, vol. 14(2), pp. 268-275, (May 2006). |
| Lam et al., “T-Cell Therapies for HIV,” Immunotherapy, Future Medicine, vol. 5(4), pp. 407-414, (Apr. 2013). |
| Munoz et al., “Ex Vivo Expansion and Lentiviral Transduction of Macaca Nemestrina CD4 + T Cells,” Journal of Medical Primatology, vol. 38(6), pp. 438-443, (Dec. 2009). |
| Porichis et al., “HIV-Specific CD4 T Cells and Immune Control of Viral Replication,” Current Opinion in HIV and Aids, vol. 6(3), pp. 174-180, (May 2011). |
| Kavanagh et al., “Expansion of HIV-Specific CD4+ and CD8+ T Cells by Dendritic Cells Transfected with mRNA Encoding Cytoplasm- or Lysosome-Targeted Nef,” Blood, American Society of Hematology, vol. 107(5), pp. 1963-1969, (Mar. 2006). |
| Akinsheye et al., “Fetal Hemoglobin in Sickle Cell Anemia,” Blood, vol. 118(1), pp. 19-27, (2011). |
| Lin et al., “Up-Regulation of Bcl-2 is Required for the Progression of Prostate Cancer Cells from an Androgen-Dependent to an Androgen-Independent Growth Stage,” Cell Research, vol. 17, pp. 531-536, (2007). |
| Lee et al., “Lentiviral delivery of short hairpin RNAs protects CD4 cells from multiple clades and primary isolates of HIV.” Blood, 2005, vol. 106(3):818-826. (Year: 2005). |
| Choi et al., “Multiplexing Seven miRNA-Based shRNAs to Suppress HIV Replication.” Molecular Therapy, 2015, vol. 23(2):310-320. Supplementary materials. |
| Spartevello et al., Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach, Molecular Therapy—Nucleic Acids, 2016, vol. 5:1-12. |
| Blites, C., M. Abrahao, P. Bozza, E. M. Netto, A. Lyra and F. Bahia (2018). “Infection by HTLV-1 Is Associated with High Levels of Proinflammatory Cytokines in HIV-HCV-Coinfected Patients.” J Acquir Immune Defic Syndr 77(2): 230-234. |
| Douek, D. C., J. M. Brenchley, M. R. Betts, D. R. Ambrozak, B. J. Hill, et al. (2002). “HIV preferentially infects HIV-specific CD4+ T cells.” Nature 417(6884): 95-98. |
| Eguchi, K., N. Matsuoka, H. Ida, M. Nakashima, M. Sakai, et al. (1992). “Primary Sjogren's syndrome with antibodies to HTLV-I: clinical and laboratory features.” Ann Rheum Dis 51(6): 769-776. |
| Futsch, N., R. Mahieux and H. Dutartre (2017). “HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.” Viruses, 10, 1; doi:10.3390/v10010001. |
| Gessain, A., F. Barin, J. C. Vernant, O. Gout, L. Maurs, A. Calender and G. de The (1985). “Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.” Lancet 2(8452): 407-410. |
| Gessain, A. and O. Cassar (2012). “Epidemiological Aspects and World Distribution of HTLV-1 Infection.” Front Microbiol 3: 388. |
| Goncalves, D. U., F. A. Proietti, J. G. Ribas, M. G. Araujo, S. R. Pinheiro, A. C. Guedes and A. B. Carneiro-Proietti (2010). “Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.” Clin Microbiol Rev 23(3): 577-589. |
| Kagdi, H., M. A. Demontis, J. C. Ramos and G. P. Taylor (2018). “Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T-lymphotropic virus type 1 infection.” PLoS Pathog 14(2): e1006861. |
| Kagdi, H. H., M. A. Demontis, P. A. Fields, J. C. Ramos, C. R. Bangham and G. P. Taylor (2017). “Risk stratification of adult T-cell leukemia/lymphoma using immunophenotyping.” Cancer Med 6(1): 298-309. |
| Macnamara, A., A. Rowan, S. Hilburn, U. Kadolsky, H. Fujiwara, et al. (2010). “HLA class I binding of HBZ determines outcome in HTLV-1 infection.” PLoS Pathog 6(9): e1001117. |
| Manel, N., F. J. Kim, S. Kinet, N. Taylor, M. Sitbon and J. L. Battini (2003). “The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV.” Cell 115(4): 449-459. |
| Martinez, M. P., J. Al-Saleem and P. L. Green (2019). “Comparative virology of HTLV-1 and HTLV-2.” Retrovirology 16(1): 21. |
| Mochizuki, M., T. Watanabe, K. Yamaguchi, K. Takatsuki, K. Yoshimura, et al. (1992). “HTLV-I uveitis: a distinct clinical entity caused by HTLV-I.” Jpn J Cancer Res 83(3): 236-239. |
| Mosley, A. J., B. Asquith and C. R. Bangham (2005). “Cell-mediated immune response to human T-lymphotropic virus type I.” Viral Immunol 18(2): 293-305. |
| Nagai, M. and M. Osame (2003). “Human T-cell lymphotropic virus type I and neurological diseases.” J Neurovirol 9(2): 228-235. |
| Yamano, Y. and T. Sato (2012). “Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.” Front Microbiol 3: 389. |
| Nishioka, K., I. Maruyama, K. Sato, I. Kitajima, Y. Nakajima and M. Osame (1989). “Chronic inflammatory arthropathy associated with HTLV-I.” Lancet 1(8635): 441. |
| Osame, M., K. Usuku, S. Izumo, N. Ijichi, H. Amitani, et al. (1986). “HTLV-I associated myelopathy, a new clinical entity.” Lancet 1(8488): 1031-1032. |
| Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna and R. C. Gallo (1980). “Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.” Proc Natl Acad Sci U S A 77(12): 7415-7419. |
| Poiesz, B. J., F. W. Ruscetti, J. W. Mier, A. M. Woods and R. C. Gallo (1980). “T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor.” Proc Natl Acad Sci U S A 77(11): 6815-6819. |
| Roc, L., C. de Mendoza, M. Fernandez-Alonso, G. Reina, V. Soriano and H. N. Spanish (2019). “Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals.” Ther Adv Infect Dis 6: 2049936119868028. |
| Soker, S., S. Takashima, H. Q. Miao, G. Neufeld and M. Klagsbrun (1998). “Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.” Cell 92(6): 735-745. |
| Uchiyama, T., J. Yodoi, K. Sagawa, K. Takatsuki and H. Uchino (1977). “Adult T-cell leukemia: clinical and hematologic features of 16 cases.” Blood 50(3): 481-492. |
| Dickler, H. B., et al. (1973). “Lymphocyte binding of aggregated IgG and surface Ig staining in chronic lymphocytic leukaemia.” Clin Exp Immunol 14(1): 97-106. |
| Hassan et al., “Isolation of umbilical cord mesenchymal stem cells using human blood derivative accompanied with explant method,” Stem Cell Investigation, pp. 1-8, (2019). |
| Huang et al., “An Efficient protocol to generate placental chorionic plate-derived mesenchymal stem cells with superior proliferative and immunomodulatory properties,” Stem Cell Research & Therapy, pp. 1-15, (2019). |
| Quan Jun-Jie et al., “Parp3 interacts with FoxM1 to confer glioblastoma cell radio resistance”, Tumor Biology, Karger, Basel, CH, vol. 36, No. 11, Jun. 4, 2015 (Jun. 4, 2015), pp. 8617-8624, XP036217799, ISSN: 1010-4283, DOI: 10.1007/S13277-015-3554-4 [retrieved on Jun. 4, 2015] *whole document*. |
| Jakobsson J. and Lundberg C.: “Lentiviral 1, 2, 4-10 vectors for use in the central nervous system”, Molecular Therapy: The Journal of the American Society of Gene Therapy, Cell Press, US, vol. 13, No. 3, Mar. 1, 2006 (Mar. 1, 2006), pp. 484-493, XP005326761, ISSN: 1525-0016, DOI: 10.1016/ J.Ymthe.2005.11.012 *the whole document*. |
| Yun Jong Lee et al., “Poly (ADP-ribose) in 1-15 the pathogenesis of Parkinson's disease”, BMB Reports, vol. 47, No. 8, Aug. 31, 2014 (Aug. 31, 2014), pp. 424-432, XP55671927, KR, ISSN: 1976-6696, DOI: 10.5483/BMBRep.2014.47.8.119 *the whole document*. |
| Lang Yoo et al., “Parp-1 regulates the expression of caspase-11”, Biochemical and Biophysical Research Communications, vol. 408, No. 3, Apr. 22, 2011 (Apr. 22, 2011), pp. 489-493, XP028209824, ISSN: 0006-291X, DOI: 10.1016/ J. BBRC.2011.04.070 [retrieved on Apr. 22, 2011] *whole document*. |
| Tae-In Kam et al., “Poly (ADP-ribose) derived pathologic [alpha]—synuclein neurodegeneration in Parkinson's disease”, Science, vol. 362, No. 6414, Nov. 1, 2018 (Nov. 1, 2018), p. eaat8407, XP55672116, US, ISSN: 00368075, DOI: 10.1126/science. aat8407 *whole document*. |
| Olsen A.L. and Feany M.B., “PARP Inhibitors and Parkinson's Disease”, Jan. 1, 2019 (Jan. 1, 2019), XP55672111, retrieved from the Internet: URL: https://mfprac.com/web2019/07literature/literature/Neurology/ParkinsonPARPI_Olsen.pdf [retrieved on Feb. 27, 2020] *the whole document*. |
| Richard Lu et al., “Siman Virus 40-Based Replication of Catalytically Inactive Human Immunodeficiency Virus Type 1 Integrase Mutants in Nonpermissive T Cells and Monocyte-Derived Macrophages”, Journal of Virology, Jan. 2004, p. 658-668. DOI: 10.1128/JVI.78.2658-668.2004. |
| FM Sverdrup et al., “Development of human papillomavirus plasmids capable of episomal replication in human cell lines”, Gene Therapy, Mar. 26, 1999, p. 1317-1321, Retrieved from the Internet: URL: http://www.stockton-pressco.uk/gt. |
| Kathleen Van Craenenbroeck et al., “Episomal vectors for gene expression in mammalian cells”, Eur J. Biochem, vol. 267, p. 5665-5678, Jul. 14, 2000. |
| Hee Yeon Kim., “Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness,” Experimental & Molecular Medicine, (2018). |
| Hong Wang., “Indirect Stimulation of Human V2V2 Cells Through Alterations in Isoprenoid Metabolism,” The Journal of Immunology, (2011). |
| Z. Li, “Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis in vitro,” Clinical & Experimental Immunology, (2014). |
| Xiaofeng Jiang, “A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate in B2-adrenerigic receptor internalization and down-regulation,” The FASEB Journal, vol. 26, pp. 1-13(1995). |
| Jian Yang, “Lentiviral-Mediated Silencing of Farnesyl Pyrophosphate Synthase through RNA Interference in Mice,” Biomed Research International, vol. 2015, Article ID 914026, 6 pages, (2015). |
| Yang Ye, “Knockdown of farnesyl pyrophosphate synthase prevents angiotensin II-medicated cardiac hypertrophy,” The International Journal of Biochemistry & Cell Biology, vol. 42, pp. 2056-2064, (2010). |
| Jianqiang Li, “Reduced Expression of Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by V9V2 Cells,” The Journal of Immunology, pp. 8118-8124, (2019). |
| Daryl S. Schiller, “Parameters Influencing Measurement of the Gag Antigen-Specific T-Proliferative Response to HIV Type 1 Infection,” AIDS Research and Human Retroviruses, vol. 16, No. 3, pp. 259-271, (2000). |
| Bergvall et al. “The E1 proteins”, Virology 445; p. 35-56, (Year:2013). |
| McBride, A., “The Papillomavirus E2 proteins”, Virology 445: p. 57-79, (Year: 2013). |
| Chiang C-m et al., “Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins.” PNAS 89: p. 5799-5803, (Year: 1992). |
| Jaalouk, et al. “A Self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression engineered t-cells,” Virology Journal: p. 1-12, (Year: 2006). |
| Cronin et al., “Altering the Tropism of Lentiviral Vectors through Pseudotyping”, Curr Gene Ther, Aug. 2005, vol. 5(4), pp. 687-398. |
| Cannon et al., “Pseudotype-Dependent Lentiviral Transduction of Astrocytes or Neurons in the Rat Substantia Nigra”, Experimental Neurology, vol. 228, (Year: 2011), pp. 41-52, doi:10.1016/J.expneurol.2010.10.016. |
| Nada et al, “Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation”, Journal for Immunotherapy of Cancer, vol. 5, No. 1, (Feb. 21, 2017), pp. 1-23, (2017) DOI 10.1186/s40425-017-0209-6 *the whole document*. |
| Benyamine et al., “BTN3A molecules considerably improve Vy9Vδ2T cells-based immunotherapy in acute myeloid leukemia,” Oncolmmunology, vol. 5, No. 10, 10 pages, (Oct. 2, 2016), E1146843 *the whole document*. |
| Harly et al., “Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset,” American Society of Hematology , vol. 120, No. 11, (Sep. 13, 2012), pp. 2269-2279, XP055081172, ISSN: 0006-4971, DOI: 10.1182/blood-2012-05-430470 *the whole document*. |
| Wang et al., “Intravenous Delivery of SiRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis”, Molecular Therapy, pp. 1919-1929, vol. 21, No. 10, Oct. 2013. |
| Yang et al., “Construction of PARP-1 gene silencing cell lines by lentiviral-mediated RNA interference,” School of Public Health, Guangdong Medical College, Abstract (2009). |
| Zhaobing Ding et al., “Liver-Directed, AAV-and Lentivirus-Mediated Gene Therapy in the Phenylketonuria Mouse Model Pah-enu2”, Molecular Therapy, vol. 11, Supp. 1. (May 2005) XP055751452. |
| Ledley et al., “Retroviral-mediated gene transfer of human phenylalanine hydroxylase into NIH 3T3 and hepatoma cells”, Proceedings of the National Academy of Sciences, vol. 83, No. 2. (Jan. 1, 1986), pp. 409-413, XP002583115. |
| Ledley et al., “Molecular biology of phenylalanine hydroxylase and phenylketonurina”, Trends in Genetics, Elsevier Science Publishers B.V. Amsterdam, NL, vol. 1. (Jan. 1, 1985), pp. 309-313, XP025943064. |
| EPO; Examination Report dated Oct. 1, 2021 in Application No. 16904834.5. |
| USPTO; Corrected Notice of Allowance dated Apr. 13, 2021 in the U.S. Appl. No. 16/687,525. |
| USPTO; Issue Notification dated May 18, 2021 in the U.S. Appl. No. 16/687,525. |
| EP Office Action in European Application No. 16808223.8, dated Feb. 2, 2021, 5 pages. |
| EP Office Action in European Application No. 16808223.8, dated Oct. 12, 2021, 4 pages. |
| JP Office Action in Japanese Application No. 2018-563822, dated Jul. 15, 2021, 10 pages (with English translation). |
| JP Office Action in Japanese Application No. 2018-563892, dated Jul. 2, 2021, 11 pages (with English translation). |
| JP Office Action in Japanese Application No. 2021-021627, dated Sep. 29, 2021, 4 pages (with English translation). |
| LaFountaine et al., “Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9”, Intl Journal of Pharmaceutics, Oct. 2015, 494(1):180-194. |
| O'Connor et al., “Transcription factor binding sites in the long control region of genital HPVs”, Human papillomaviruses, Oct. 1995, 20 pages. |
| U.S. Final Office Action in U.S. Appl. No. 15/580,661, dated Aug. 20, 2021, 20 pages. |
| U.S. Non-Final Office Action in U.S. Appl. No. 16/308,335, dated Nov. 29, 2021, 17 pages. |
| Wang et al., “HIV Vaccine Research: The Challenge and the Way Forward,” Journal of Immunology Research, vol. 2015, Article ID 503978, 5 pages. |
| Bourguigon et al., “Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients,” Journal of Immunological Methods, vol. 414, p. 1-10 (2014). |
| Briz et al., “Validation of Generation 4 Phosphorus-Containing Polycationic Dendrimer for Gene Delivery Against HIV-1,” Current Medical Chemistry, vol. 19, p. 5044-5051, (2012). |
| Anderson et al., “Preintegration HIV-1 Inhibition by a Combination Lentiviral Vector Containing a Chimeric TRIM5a Protein, a CCR5 shRNA, and TAR Decoy,” Molecular Therapy, vol. 17, No. 12, p. 2103-2114, Dec. 2009. |
| JP; Japanese Office Action in the Application No. 2017-567175 dated Jun. 15, 2020. |
| EPO; Extended European Search Report in the Application No. 18736295.9 dated Aug. 20, 2020. |
| USPTO; Notice of Allowance dated Jul. 10, 2020 in the U.S. Appl. No. 16/530,908. |
| USPTO; Final Office Action dated Jul. 27, 2020 in the U.S. Appl. No. 16/076,655. |
| JP; Japanese Office Action in the Application No. 2018-536892 dated Jun. 26, 2020. |
| US, Office Action issued in U.S. Appl. No. 16/308,335 on Oct. 6, 2023. |
| JP, Office Action issued in Japanese Application No. 2022-172256 on Oct. 19, 2023. |
| Nakahara et al., “Regulation of Human Papillomavirus (HPV) Genome Replication in the Viral Life Cycle and Its Association with the Viral Persistence and Cancer Development,” Virus, 64(1), pp. 57-66, 2014. |
| EP, Office Action issued in European Patent Application No. 16808223.8 on Nov. 9, 2023. |
| Sailaja et al., “Many Different Papillomaviruses Have Low Transcriptional Activity in Spite of Strong Epithelial Specific Enhancers, ” Journal of General Virology, 80, 1715-1724, 1999. |
| BR Office Action in Application No. BR112018075399-8 dated Jan. 16, 2024. |
| KR Office Action in Application No. 10-2023-7041421 dated Jan. 22, 2024. |
| Number | Date | Country | |
|---|---|---|---|
| 20190264226 A1 | Aug 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62431760 | Dec 2016 | US | |
| 62347552 | Jun 2016 | US |
